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1 Introduction 
 
1.1 Acute myeloid leukemia 
 
Acute Myeloid Leukemia is a malignant disorder which affects myeloid 
development or myelopoiesis. Myelopoiesis begins with the differentiation of 
a small pool of pluripotent stem cells into the most primitive myeloid 
progenitors. These progenitors develop into myeloid precursors, which 
subsequently follow a specific differentiation program and lineage 
commitment controlled by lineage specific transcription factors and newly 
discovered micro RNAs (Shivdasani, 2006). This process ultimately results in 
the development of mature neutrophils, eosinophils, basophils and monocytes, 
eythrocytes and megakaryocytes. The schematic representation of myeloid 
development from hematopoietic stem cell is shown as an Akashi-Kondo-
Weissman model of adult hematopoiesis (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Lineage tree of adult hematopoiesis and lymphoid-myeloid branching points (a) 
Akashi-Kondo-Weissman model of adult hematopoiesis with the branching point between 
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lymphoid and myeloid lineages indicated by the gray shaded circle. (b) Revised lineage 
tree, showing three areas where branching might occur (LT- and ST-HSC, long-term and 
short-term HSC; MPP, multipotent progenitor; ETP, early T lineage progenitor). Adapted 
from a proposed model of major hematopoietic maturation pathways from HSCs, proposed 
by Irving L. Weissman (Akashi et al., 2000). 
 
                                There have been significant advances in our 
understanding of hematopoiesis and molecular regulation of myelopoiesis. 
This has lead to the better understanding of molecular mechanisms regulating 
the development of acute myeloid leukemia. Several recent reports and studies 
of over two decades has now confirmed that transcription factors are 
commonly disrupted in AML either by their fusion as a result of chromosomal 
translocations or by point mutations. Some of the common transcription 
factors affected by these chromosomal translocations include the core binding 
factor complex, AML1, the retinoic acid receptor (RAR), GATA family of 
transcription factors, the MLL protein, and Hox proteins. Point mutations in 
myeloid transcription factors like C/EBPα and PU.1 may also lead to loss of 
normal myeloid differentiation in AML (Tenen, 2003). Besides dominant 
negative mutations of C/EBPα, which have been reported to occur in 10% of 
AML patients (Schwieger et al., 2004), also affect myeloid development. The 
chromosomal translocations, which are often associated with AML, often 
result in aberrant fusion of these transcription factors with other genes, for 
example, in t(8;21)-AML, AML1 is fused with ETO gene and in t(15;17)-
AML, PML is fused with RARA gene. These chimaeric transcription factors 
often act as a dominant negative over wild type transcription factors and are 
widely reported to be co-repressors of gene transcription. The other 
commonly disrupted transcription factors in AML include GATA1. GATA 
family of transcription factors is indispensable for hematopoiesis. GATA 1 is 
expressed at high levels in erythroid cells, megakaryocytes, mast cells, and 
eosinophils (Evans and Felsenfeld, 1989). GATA-1-deficient erythroid 
precursors fail to differentiate beyond the proerythroblast stage during the 
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lineage development of erythrocytes. PU.1 and GATA factors have antagonist 
functions in the hematopoietic development. For example, GATA-1 blocks 
PU.1 transactivation by blocking its binding of PU.1 coactivator c-jun. 
Besides PU.1 inhibits GATA-1 transactivation by inhibiting its binding to 
DNA (Nerlov et al., 2000). A recently discovered myeloid specific 
transcription factor MafK has been reported to play a crucial role in specifying 
transcription of erythroid specific genes. C/EBPα is a well known and 
extensively investigated lineage specific transcription factor. This 
transcription factor is required for the development of CMP (common myeloid 
progenitors) to GMP (granulocyte/ macrophage progenotors). Figure 2; 
describes the role of various transcription factors in myeloid lineage 
commitment decisions. C/EBPα inhibits cell cycle progression via interaction 
with E2F1 and additional mechanisms, and stimulates cell survival by 
inducing bcl-2 in cooperation with NF-κB (Wang et al., 2003). C/EBPα–/– 
hematopoietic cells derived form adult bone marrow do not generate 
granulocyte-monocyte progenitors (GMPs) from the common myeloid 
progenitor (CMP) (Heath et al., 2004).  
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Figure 2. Role of transcription factors in hematopoietic development. The common 
myeloid progenitor (CMP) gives rise to granulocyte/macrophage progenitors (GMPs) and 
megakaryocyte/erythroid progenitors (MEPs). Upregulation of the transcription factor PU.1 
is essential for the transition from HSC to CLP, whereas downregulation of PU.1 is 
required for the differentiation of CMP to MEP. CCAAT/enhancer binding protein-  
(C/EBP ) upregulation initiates the transition from CMP to GMP. One hypothesis is that 
the 'default' pathway involves differentiation of GMPs to monocytes and macrophages, 
which depends on PU.1 activity. In this model, C/EBP  subverts this default monocytic 
pathway and promotes differentiation into granulocytes. Adapted from Nature Reviews 
Cancer (Tenen, 2003). 
1.2 Chromosomal translocations in AML 
 
Acute myeloid leukemia is a disease of molecular alterations and genomic 
instability that disrupt almost every aspect of cellular biology. These include 
the regulation of cell proliferation, differentiation, self-renewal, cell cycle 
checkpoint control, DNA repair mechanism and chromatin stability, and cell 
migration. One of the important features of acute myeloid leukemia is the 
occurrence of cytogenetic abnormalities. Cytogenetic analysis for AML 
patients provides some of the strongest information available for the disease 
(prognosis), predicting the outcome of the disease remission and effectiveness 
of the therapy besides overall survival rates (Marcucci et al., 2004).The 
cytogenetic abnormalities involving translocations of t(8;21), t(15;17) or 
inv(16) are associated with favourable prognosis that means they respond 
positively to the therapy and the chances of cure for the disease is higher 
(Grimwade et al., 1998). The group of AML that is characterized by 
aberrations of chromosomes 5 and 7 or abnormalities of 11q23 shows a poor 
response to chemotherapy (Schoch et al., 2005). Finally, there is a 
heterogeneous group of patients who do not show any apparent cytogenetic 
aberrations and are grouped as normal karyotype AML. This group is 
considered an intermediate AML risk group (Bienz et al., 2005). Because of 
the importance of cytogenetics in AML the classification of AML has been 
revised by World Health Organization (Cheson et al., 1990). While the 
elements of the French-American-British (FAB) classification largely based 
on morphology, immunophenotype, cytogenetics and clinical features have 
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been retained. The WHO classification incorporates more recent discoveries 
regarding the genetics, clinical and prognostic features of AML. This is an 
attempt to classify entities that are homogeneous biologically and that have 
prognostic and therapeutic relevance. The WHO classification of AML is 
shown as table1.  
 
Table 1. WHO classification of AML. Adapted from (Bennett et al., 1985) proposed 
revised criteria for the classification of AML. 
 
 AML with characteristic genetic abnormalities 
                AML with t(8;21)(q22;q22); AML1/ETO 
                AML with inv(16)(p13q22) or t(16;16)(p13;q22); (CBFβ/MYH11) 
                Acute promyelocytic leukemia AML with t(15;17)(q22;q12); (PML/RARα) and  
                 variants  
                AML with 11q23 (MLL) abnormalities 
                AML with FLT3 mutation   
AML with multilineage dysplasia 
AML and MDS, therapy related  
                 Alkylating agent-related AML and MDS 
                  Topoisomerase II inhibitor-related AML 
AML not otherwise categorized 
                Acute myeloblastic leukemia minimally differentiated (FAB Classification M0)                            
                Acute myeloblastic leukemia without maturation (FAB Classification M1) 
                Acute myeloblastic leukemia with maturation (FAB Classification M2) 
                Acute myelomonocytic leukemia (AMML) (FAB Classification M4) 
                Acute monoblastic leukemia and acute monocytic leukemia (FAB classifications      
                 M5a and M5b) 
                Acute erythroid leukemias (FAB classifications M6a and M6b) 
                Acute megakaryoblastic leukemia (FAB Classification M7) 
                                       AML/transient myeloproliferative disorder in Down syndrome 
                Acute basophilic leukemia                                                                                                                
                Acute panmyelosis with myelofibrosis 
                Myeloid sarcoma 
Acute leukemias of ambiguous lineage 
 
 
                                        The balanced chromosomal translocations as well as 
aberrant complex translocations (involving multipule translocations and 
deletions) are the common occurrence in leukemia. These translocations are 
important prognostic markers and have been used in disease diagnosis and 
treatment induction. Common targets of these translocations are the 
transcription factors that are indispensable for hematopoiesis. The abnormal 
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expression of these chimaeric transcription factors target other oncogenes and 
leads to disease progression through unknown mechanisms. The targets of 
these translocations are described below in detail: 
1.2.1 The core binding factor complex  
 The core binding factor complex consists of a heterodimer of the Runx1 
(formerly AML1) and CFBß protein and normally activates a number of genes 
critical for normal myeloid development. In AML this transcription factor is 
disrupted by at least three different translocations: t(8;21), which generates the  
AML1-ETO fusion; inv(16), yielding the CBFß-MYH11 fusion; and t(3;21), 
which generates the RUNX1-EVI1 fusion protein associated with MDS and 
therapy-related AML. All of these fusions act as dominant negative over the 
core binding factor complex. AML1 is the DNA-binding subunit of the core-
binding transcription factor (CBF) and binds to the enhancer core sequence 
TGT/cGGT, which has been shown to be important in the transcriptional 
regulation of a number of viral and cellular genes (Wang et al., 1993); 
(Meyers et al., 1993). DNA-binding activity of AML1 is mediated through a 
central 118 amino acid domain that is homologous to the Drosophila pair-rule 
protein Runt (hence its designation as the Runt homology domain, or RHD) 
(Crute et al., 1996; Daga et al., 1992) and its affinity for DNA binding is 
increased through heterodimerization through the RHD with a second non-
DNA-binding subunit CBFβ (Figure 3) (Wang et al., 1993).  
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Figure 3. The AML1/CBFβ transcription factor complex binds to the core enhancer 
sequence and functions as an enhancer organizing factor to induce gene transcription. Other 
proteins in this complex differ according to the particular promoter or enhancer involved. 
They include the transcription factors Ets-1 or Ets family members, C/EBP-α, the 
transcriptional coactivators ATEF/CREB and P300/CBP, and the DNA-bending protein 
LEF-1, which interacts with AML1 through an adapter protein called ALY. Among the 
genes whose transcription is regulated by AML1 are: myeloperoxidase (MPO), the receptor 
for colony-stimulating factor 1 (CSF-1R), and the subunits of the T-cell antigen receptor 
(TCR). Binding of the AML/CBFβ complex to DNA normally leads to transcriptional 
activation; however, when it is complexed with either Groucho or the Ear2 protein, its 
activity is converted to that of a transcriptional repressor. Adapted from British Journal of 
Haematology review (Downing, 1999). 
 
                                            The t(8;21) translocation which involves AML1 
transcription factor is reported in 10–15% of AML patients and is frequently 
the only cytogenetic abnormality present in the leukemic blasts. (Bitter et al., 
1987). Patients with this subtype of AML typically present FAB AML-M2 
morphology. Patients with this translocations generally respond positively to 
induction therapy and have prolonged disease free survival (Bloomfield et al., 
1998), however, when associated with extra mutations in Flt3 or deletions of 
chromosomes, the penetration of disease and prognosis are severe. The 
translocation t(8;21)(q22;q22) involves the AML1 gene and ETO (eight-
twenty-one) gene. The transcriptional activation domains of AML1 are deleted 
and replaced by ETO sequences known to interact with nuclear co-repressors 
like N-COR or SMRT and HDACs (Figure 4). This associated of ETO with 
these corepressors produce secondary effects of histone deacetylation and 
recruits methyltransferase contributing to abnormally stable corepression 
complex (Ferrara et al., 2001; Racanicchi et al., 2005). This chimaeric protein, 
AML1-ETO, target the promoters of AML1 target genes and directly 
represses AML1-mediated transcriptional activation in transient transcription 
assays (Meyers et al., 1995).  It represses genes usually activated by AML1, 
including c-FMS, (Follows et al., 2003) p14 ARF (Hiebert et al., 2003), and 
C/EBPα (Pabst et al., 2001). The AML1 family of transcription factors 
recognize the binding sequence TGT/yCGGT (Erickson et al., 1992) in a 
 8
number of genes including M-CSF receptor, GM-CSF, myeloperoxidase and 
neutrophil elastase through a 117-amino acid region that is highly homologous 
to the Drosophila segmentation gene runt (Erickson et al., 1992; Meyers et al., 
1993). AML1-ETO complexes retain the ability to bind to the core sequence 
and activates the transcription of number of genes (Yergeau et al., 1997; 
Zhang et al., 1996). AML1-ETO inhibits gene activation by inactivating 
hematopoiesis promoting transcription factors like AML1 and C/EBPα. 
However, little is known about the exact mechanism of AML1-ETO mediated 
inhibition and/or activation of target genes. 
 
 
 
 
 
 
 
Figure 4. The AML1-ETO fusion protein retains the ability to bind to the core enhancer 
sequence and to heterdimerize with CBFβ. In contrast to wild-type AML1, this fusion 
protein binds through its ETO sequences to both ETO/MTG family members such as 
MTGR1 and MTG16, and to a corepressor complex. This co repressor interaction results in 
the repression of genes whose transcription is normally activated by AML/CBFβ. Among 
the target genes affected are: myeloperoxidase (MPO), the receptor for colony-stimulating 
factor 1 (CSF-1R), and the subunits of the T-cell antigen receptor (TCR). Adapted from 
British Journal of Haematology review (Downing, 1999). 
1.2.2 Acute promyelocytic leukemia  
APL occurs in 5%-9% of AML cases and is associated with promyelocytes 
blasts with a FAB M3 subtype. In APL, the retinoic acid receptor alpha 
(RARα) gene on 17q12 fuses with a nuclear regulatory factor on 15q22 
(promyelocytic leukemia or PML gene) resulting in a PML-RARα gene fusion 
transcript (Caligiuri et al., 1997). A rare type of masked t(15;17) also occur 
and is associated with complex variant translocation leading to the 
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submicroscopic insertion of the RARα gene into PML gene leading to the 
expression of the PML-RARα fusion transcript called M3v (Le Beau et al., 
2002). The translocation t(11;17) results in the PLZF-RARα fusion and is 
reported in 1% of AML which is a retinoic acid resistant form of disease. APL 
patients respond positively to the ATRA and arsenic acid treatment and show 
good prognosis. The other drugs tested are the histone deacetylase inhibitor 
valproic acid, either alone or in combination with ATRA, has provided 
evidence of differentiation and decreased blast counts in patients (Kuendgen et 
al., 2004). PML and all of the fusion partner proteins in APL have been shown 
to form multimeric complex with RXR. Like AML1-ETO, PML-RARα also 
acts as dominant negative over RARα. PML-RARα has been shown to recruit 
DNA methyl transferases to promotors contributing to the transcriptional 
suppression (Di Croce et al., 2002). Recenty it was reported that a cleavage of 
the PML-RARα fusion protein by neutrophil elastase (NE) was required for 
the development of APL like disease (Lane and Ley, 2003). 
1.2.3 Acute myeloid leukemia with 11q23 (MLL) abnormalities  
AML with 11q23 abnormalities comprises 5% to 6% of cases of AML and is 
typically associated with acute myelomonocytic, monoblastic, and monocytic 
leukemia (FAB classifications M4, M5a and M5), respectively. The MLL 
gene on 11q23, a developmental regulator, has been reported to be involved in 
translocations with 22 different partner chromosomes. 11q23 is involved with 
the complex  translocations like t(11;22) (q23;q12), t(4;11) (q21;q23), t(9;11) 
(q22;p13.1) (Giugliano et al., 2002). Patients with t(11;19)(q23;p13.1) have 
poor outcome and are considered  high risk AML (Byrd et al., 2002). Unlike 
other fusion proteins MLL is an activator protein that binds with the specific 
DNA sequences notably to the Hox gene promoters. MLL is required for 
Hoxc8 expression, it binds and methylates histones at the Hox loci (at histone 
H3 lysine 4), leads to the activation of target genes (Milne et al., 2002).  Hox 
gene expression in turn is associated with increased self-renewal by 
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hematopoietic cells. MLL-fusion proteins have the ability to dimerize with 
themselves and wild-type MLL. Some MLL fusion proteins may directly 
target Hox genes for activation by random recruitment of activators, for 
example, the MLL-CBP fusion can directly target histone acetyl transferases 
to target genes (Wang et al., 2005). The distribution of AML cytogenetic 
among the population is shown (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Shows the distribution of AML subtypes with recurrent cytogentic abnormalities 
and FAB subtype (Rabbitts and Stocks, 2003). Adapted from Science Magazine (Look, 
1997).  
 
1.3 Survivin 
Survivin belongs to the family of IAPs (inhibitor of apoptosis) proteins (Li et 
al., 1998b) and is characterised by the presence of 70 amino acid Zinc-finger 
fold called Baculovirus IAP repeat (BIR). IAP family members besides BIR 
domain possess a caspase recruitment domain (CARD) and a C-terminal 
RING FINGER domain. Survivin is the only member of the family which 
lacks C-terminal RING FINGER domain (Salvesen and Duckett, 2002). A 
single copy of survivin gene transcribes two other transcript variants in 
addition to 426 bp survivin. One transcript variant is generated by the 
 
 11
insertion of an alternative exon 2 (survivin 2B) and the third variant is 
generated by the deletion of exon 3 (survivin ∆Ex3) (Mahotka et al., 1999) 
(Figure 6).  
 
 
 
 
 
 
 
Figure 6. Structure and organization of survivin proteins generated by the alternative 
splicing of survivin gene. Survivin-2B is generated by the alternative insertion of exon 2 
and survivin ∆Ex3 is result of deletion of exon 3. Discrete regions are indicated that are 
implicated in dimerization with other isoforms, microtubule binding, nuclear localisation 
etc. Figure adapted from Nature Reviews Cancer (Altieri, 2003). 
                                            Survivin expression is regulated by many 
signalling pathways and its expression goes up during the G2/M phase of cell 
cycle. It is a microtubule regulatory protein and is a part of the chromosomal 
passenger complex (CPC) consisting of the serine/threonine kinase Aurora B, 
the inner centromere protein INCENP and Borealin/DasraB which has 
essential functions at the centromere in ensuring correct chromosome 
alignment and segregation (Vagnarelli and Earnshaw, 2004). Survivin is an 
antiapoptotic protein and is involved in many apoptotic pathways in 
conjunction with bcl2. In general mammalian cells use two main pathways to 
undergo apoptosis. An extrinsic pathway initiated by the ligation of cell-
surface death receptors, including the tumour necrosis factor-α (TNFα) 
receptor and CD95 (Krammer, 2000). An intrinsic pathway mostly initiated by 
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intracellular and environmental signals and is centred on dysregulation of 
mitochondrial functions (Wang, 2001). The result is increase of mitochondrial 
membrane permeability and release of proteins into cytoplasm that facilitate 
caspase activation, most notably SMAC/DIABLO (Zhou et al., 2005) (Figure 
7).  
 
 
 
 
 
 
 
Figure 7. Apoptosis can be initiated by the intrinsic pathway governed by mitochondria 
and acts through caspase 9 and extrinsic pathway regulated by caspase 8. Both pathways 
converge to activate the effector caspases, which act on the death substrates. In addition, 
cell death is regulated by the BCL2 and inhibitor of apoptosis (IAP) proteins. BCL2 act to 
regulate mitochondria permeability by activating BAX and BID; whereas IAP proteins act 
downstream to prevent processing of initiator caspase-9 from the apoptosome. Proteins that 
are released by mitochondria during the permeability transition, including cytochrome c 
and SMAC/DIABLO, facilitate caspase activation by forming the apoptosome or relieving 
the caspase-inhibitory function of IAP proteins, respectively. Adapted from Nature 
Reviews Cancer (Altieri, 2003). 
                                          Interestingly, survivin expression is undetectable in 
most normal adult tissues, however, its expression enhances dramatically with 
tumor progression and also in human leukemia including AML (Wagner et al., 
2006). With respect to hematopoietic system a low level of survivin 
expression has been shown to be important for megakaryopoiesis. During the 
course of this study we further report that AML1-ETO fusion specifically 
Intrinsic
Extrinsic
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activates survivin expression. Further investigation revealed that by knock 
down of survivin expression, AML1-ETO mediated inhibition of granulocytic 
differentiation (Pabst et al., 2001) was overcome significantly through the 
restoration of C/EBPα activity (Balkhi et al; unpublished data).  
1.3.1 Suvivin as a potential therapeutic target for AML 
Survivin expression is undetectable in most normal adult tissues, however, its 
expression enhances dramatically in tumor tissues and human leukemia 
including AML (Wagner et al., 2006). Survivin also serves, in some instances, 
is an independent prognostic marker. Survivin expression, however, is not 
involved in major differentiation steps within myeloid cell maturation which 
is in contrast to XIAP whose expression correlates with monocytic 
differentiation in therapy related AML (Tamm et al., 2004). With respect to 
hematopoietic system survivin has been shown to express at low levels in 
human umbilical-cord blood and bone-marrow derived CD34+ cells and is 
rapidly enhanced with cytokine incubation (Fukuda and Pelus, 2001). 
Survivin also has an important role in the survival of terminally differentiated 
neutrophils and is highly expressed in immature neutrophils (Altznauer et al., 
2004). In many instances the clinical outcome of patients with AML is 
correlated with altered levels of pro-apoptotic and pro-survival molecules in 
leukemic cells. Expression of the bcl-2 survival molecule, the survivin and the 
extrinsic death pathway protein FADD are predictive of clinical response rates 
and survival in AML. Survivin has assumed a great therapeutic significance 
because of two main reasons; it is differentially expressed in cancer and is 
required to maintain cancer viability. Survivin based therapy would thus be 
expected to exert limited toxicity on normal tissues and at promoting the 
leukemic cell death. These approaches has been independently validated by 
several groups reporting that T cells mount a vigorous cytolytic response 
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against survivin peptides in vitro and in vivo (Hirohashi et al., 
2002);(Rohayem et al., 2000). 
1.4 Self-renewal and AML 
The normal progenitor cells from the hematopoietic system are committed to a 
particular hematopoietic lineage, however, the hematopoietic stem cells like 
long term HSCs maintain a colony of stem cells that have a potential to self 
renew. Leukemic cells from patients with AML can undergo extensive self-
renewal rather than lineage-specific commitment. Moreover, the leukemic 
stem cell population in AML is functionally heterogeneous with differing 
capacities for self-renewal (Falini et al., 2005). Various explanations have 
been put forward to explain the process of self-renewal. Nucleophosmin 
(NPM) is reported to be mutated in approximately one-third of newly 
diagnosed AML, and the expression of this cytoplasmic NPM variant is 
associated with expression of genes thought to support maintenance of the 
stem cell phenotype (Alcalay et al., 2005). The FLT3-ITD mutant of AML 
and enforced expression of it, which activates proliferative and survival 
pathways, also confers the property of self-renewal in human CD34+ cells 
(Chung et al., 2005). The Wnt/ß-catenin signaling is a critical element in the 
control of self-renewal of normal and cancer stem cells. AML1-ETO fusion 
protein is known to induce the extensive self renewal of human erythroid cells 
(Tonks et al., 2003) and in human CD34+ cells (Mulloy et al., 2003). Our 
results further suggest that activation of survivin by AML1-ETO may be 
involved in the extensive self renewal property of AML1-ETO positive cells 
(Balkhi et al; unpublished data).  AML1-ETO and PML-RARα induce the 
expression of ß-catenin and γ-catenin  proteins (Muller-Tidow et al., 2004). 
Thus, the expression of tyrosine kinase mutant and fusion genes in AML 
seems to enhance the self-renewal to give a survival advantage to the 
leukemic blasts.   
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1.5 Proteomics based on mass spectrometry  
 
Proteome represent the complex set of all proteins in a cell that could be 
interacting with other proteins or proteins with specific posttranslational 
modifications. It also can be an activated set of specific genes of a given cell 
at any given time. Proteome, thus, represents a functional state of a cell and 
could provide valuable information regarding the pathological, physiological 
and differentiation state of a cell. Proteomics based on mass spectrometry 
(MS) has become an important tool for molecular and cellular biology. It 
promises the study of protein-protein interactions via affinity-based isolations 
and to precisely quantify thousands of proteins from complex samples through 
quantitaive proteomics like ICAT (Isotope-Coded Affinity Tags) and SILAC 
(stable isotope labelling of amino acids in culture). Protein analysis that 
includes the primary protein sequence, post-translational modifications or 
protein−protein interactions has been successfully used through Mass 
spectrometry. An overview of a typical proteomic experiment based on mass 
spectrometry is shown (Figure 8) 
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Figure 8. The figure gives an overview a typical proteomics experiment which consists of 
five stages. Stage 1, the proteins to be analysed are isolated from whole cell lysate or 
tissues by sample fractionation. This often includes a final step of one-dimensional gel 
electrophoresis where proteins are separated by Isoelectric focussing using different pH 
range immobiline dry strips.  Strips are loaded and separated by SDS PAGE in a 2nd 
dimension and gels are stained.  Spots are cut and digested enzymatically to peptides in 
stage 2, usually by trypsin, leading to peptides with C-terminally protonated amino acids, 
providing an advantage in subsequent peptide sequencing. In stage 3, the peptides are 
loaded on a MALDI target or processed by high-pressure liquid chromatography. After 
evaporation, multiply protonated peptides enter the mass spectrometer and, in stage 4, a 
mass spectrum of the peptides eluting at this time point is taken (MS1 spectrum, or 'normal 
mass spectrum'). The computer generates a prioritized list of these peptides for 
fragmentation and a series of tandem mass spectrometric or 'MS/MS' experiments ensues 
(stage 5). These consist of isolation of a given peptide ion, fragmentation by energetic 
collision with gas, and recording of the tandem or MS/MS spectrum. The MS and MS/MS 
spectra are typically acquired for about one second each and stored for matching against 
protein sequence databases. The outcome of the experiment is the identity of the peptides 
and therefore the proteins making up the purified protein population. Figure adapted from 
Nature (Aebersold and Mann, 2003). 
                                     The main approaches to mass spectrometric protein 
identification are the 'peptide-mass mapping'. In the 'peptide-mass mapping' 
approach proposed by Henzel and co-workers (Henzel et al., 1993), the mass 
spectrum of the eluted peptide mixture is acquired, which results in a 'peptide-
mass fingerprint' of the protein being studied. This mass spectrum is obtained 
by a relatively simple mass spectrometric method — matrix-assisted laser 
desorption/ionization (MALDI) or Nanospray ionization— which results in a 
time-of-flight distribution of the peptides comprising the mixture of 
protonated ions. Advances have been made in automation of the MALDI 
identification procedure whereby hundreds of protein spots can be excised, 
digested enzymatically, their mass spectra obtained and automatically 
searched against databases (Berndt et al., 1999; Jensen et al., 1997). In order 
to obtain the sequence of individual ions or informtaion about its post-
translation modification, specific ions from mass spectra are selected and 
fragmented either by an inert gas or by radiomagnetic waves (FTICR or Q-
TOF mass spectrometry) and captured by a 2nd time of flight. This gives a 
MSMS of the selected ions comprised of series of y, a, m, b, ions. From the 
molecular mass estimation of these ions, a sequence of a given peptide or the 
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posttranslational modification, if any, could be calculated. In recent years 
several techniques for protein quantitation by mass spectrometry have 
emerged. The accurate quantitation of proteins could provide us the valuable 
information regarding the state of a given protein. There are number of 
proteins which dramatically enhance in expression during the disease state or 
transformation. These proteins could serve as a potential drug target or 
prognostic marker. However, their accurate quantitation remains elusive. 
Quantitative mass spectrometry based on affinity tag methods like isotope-
coded affinity tags (ICAT) and metabolic labelling and stable isotope labelling 
of amino acids in culture (SILAC) (Gygi et al., 1999; Krijgsveld et al., 2003) 
are methods of choice. These techniques allow the peptides derived from two 
samples to be distinguished by mass spectrometry. The proteins are labelled 
with isotopically distinct tags (ICAT) through the incorporation of isotopically 
distinct amino acids (SILAC) in a cell culture. Protein quantitation can then be 
achieved by comparing the mass spectrum intensity of the peptides (MS 
peaks) derived from the two samples.  
                                Proteomics based on two-dimensional gel electrophoresis 
or 2DE has a potential clinical application to investigate differential 
expression data. The comparative two-dimensional gel approach which means 
the comparison between the two conditions can be used for the investigation 
of the differential regulation, up- or downregulated, in a disease-specific 
manner. This information can then be used for diagnostic, prognostic and 
therapeutic purposes. Besides the conventional staining techniques, new 
approaches have been in use for the 2DE approach. For example, to quantitate 
the protein targets, Differential ingel Electrophoresis (DIGE), which makes 
the use of flourescent probes provides a better alternative to quantiate and 
differentiate proteins between diseases versus normal state. The important 
aspect of this approach is to control the experimental conditions and variations 
among the samples. The identification of the differential proteome between 
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normal versus diseases could provide us a significant amount of information 
regarding the protein interaction networks and the signalling pathways that are 
dysregulated within a cell (Petricoin et al., 2005). An overview of differential 
proteomics is shown (Figure 9). 
 
 
 
 
 
 
Figure 9. Differential two dimensional gel approaches to investigate disease versus normal. 
Cells from two different conditions, A and B, are lysed and protein solublised. Samples are 
then applied to a 'first dimension' gel strip that separates the proteins based on their 
isoelectric points. After this step, the strip is subjected to reduction and alkylation and 
applied to a 'second dimension' SDS–PAGE gel where proteins are denatured and separated 
on the basis of size. The gels are then fixed and the proteins visualized by silver staining or 
coomassie or labelled with flourescent dyes. After staining, the resulting protein spots are 
recorded and quantified using sophisticated image software.The spots of interest are then 
excised and subjected to mass spectrometric analysis. Figure adapted from Nature (Pandey 
and Mann, 2000) 
1.5.1 Post-translational modifications (PTMs) 
 
One of the unique features offered by proteomics based studies is the ability to 
identify the post-translational modifications of proteins. These modifications 
occur posttranslationally and are not posttranscriptionally apparent from 
genomic sequence or mRNA expression data. Phosphorylation, glycosylation, 
acetylation, methylation and sulphation as well as many other modifications 
are extremely important for protein function as they affect the protein activity, 
stability, localization and turnover and could be an important target for 
therapy. One mechanism explains PTMs induce new conformational state of a 
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protein to alter its functions, for example, phosphorylation of protein kinase 
reorganises the active site of this kinase into productive conformation (Yang, 
2005). A single polypeptide can get phosphorylated at several sites; likewise 
the lysine residue of a peptide can be mono- di- or trimethylated, or mono- or 
polyubiquitylated. Furthermore, the same polypeptide chain can be modified 
by different classes of PTM, which generates an even larger number of 
possible variants (Yang, 2005). Mass spectrometry is the proteomic method of 
choice to determine these protein modifications; tandem mass spectrometry 
(MS/MS) provides a series of analytical features that are highly useful for the 
characterization of modified proteins via amino acid sequencing and specific 
detection of posttranslationally modified amino acid residues. Large-scale, 
quantitative analysis of proteins by MS/MS is beginning to reveal novel 
patterns and functions of PTMs in cellular signaling networks and 
biomolecular structure (Larsen et al., 2006). An overview of PTM detection is 
shown (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. An overview of detection of post-translational modification by MS and MSMS; 
a) shows the individual peptide peaks in the mass spectrum. The bottom panel shows how 
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sequence can be derived by fragmentation of the chosen peptide (m2) by tandem mass 
spectrometry. Phosphopeptides may be enriched by purifying the peptide mixture over a 
metal resin microcolumn. The resulting peptides can then be analysed by MALDI as shown 
before and after treatment with alkaline phosphatase. The panel shows a singly 
phosphorylated (showing a shift of 80 Da) and a doubly phosphorylated (showing a shift of 
160 Da) peptide in the MALDI spectrum. Figure adapted from Nature (Mann and Jensen, 
2003; Pandey and Mann, 2000). 
 
1.6 Aim of the study 
 
Advances in the diagnosis of cytogenetic abnormalities of AML and 
refinements in the therapeutic approaches have improved the cure for patients 
with AML. However, the survival rate among AML patients is only 30%, 
which can be attribute to not so well defined sub type specfic therapy which 
demand new findings that promises to improve further the cure rate. Recent 
advances in gene expression profiling using oligo c-DNA microarray have 
been used to differentiate cytogenetic groups and to identify new subgroups 
within the intermediate risk group of AML with normal karyotype (Bullinger 
et al., 2004). Even though transcriptomics have provided relevant information 
regarding the gene activity and cell function, however, they do not necessarily 
correlate with levels of protein expression. More importantly, such analysis 
cannot detect important posttranslational modifications of proteins (PTMs), 
such as acetylation, phosphorylation, or glycosylation. Proteomics has 
emerged as an indispensable technique to identify the proteome and 
posttranslational modifications of proteins which indeed represents the 
functional state of a cell. By undertaking such investigation an understanding 
of physiological and pathological state of a cell can be elucidated. The 
identified proteome leads to a new way of understanding the biological 
interaction in determining the disease relevant targets and pathways for the 
primary drug targets (Cristea et al., 2004). This result of this study, thus, 
provides a platform for distinguishing AML cytogentic subgroups according 
to their protein expression pattern and MS peak pattern corresponding to PTM 
differences. This might improve our ability to understand the molecular 
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differences between AML cytogenetic subgroups and would be precisely used 
for designing subtype-specific therapies. Further, by the identification of 
direct protein targets of the fusion proteins and their functional and biological 
characterisation may improve our understanding of the molecular dys- 
regulation of leukemogenesis.  
2 Materials and methods 
 
2.1 Material 
2.1.1 Mammalian cell line: 
 
Kasumi 1, human acute myeloid leukemia (AML FAB M2) established from a 
patient carrying t(8;21). Positive for AML1-ETO fusion gene (from DSMZ 
ACC 220) 
U937 (Human myeloid cell line, monoblastic) 
U937T-A/E cells (U937 cells stably transfected with AML1/ETO c-DNA, a 
tetracycline inducible cell line), kindly provided by Dr. Dong-Er Zhang. 
Human kidney 293T cells; a mouse embryonal carcinoma F9 cell line. 
HL-60 (human acute promyelocytic leukemia cell line) 
AML patient samples were kindly provided by Leukemia Diagnostic 
Laboratory, Medicine III Klinikum Großhadern, Munich. 
2.1.2 Cell culture 
 
RPMI (PAA, Cölbe, Germany) 
Foetal bovine serum (Invitrogen/GIBCO, Germany) 
Penicillin/Streptomycin (GIBCO, Germany) 
DPBS (PAN, Germany) 
DMEM (PAN, Germany) 
G-418, tetracycline, puromycin (Sigma). 
Trypsin EDTA (GIBCO, Germany) 
GlcNAc (Sigma, catalog no. A6919) 
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2.1.3 Immunoblots 
 
Phosphatase inhibitor Cocktail I and II (Sigma, Germany) 
Protease inhibitors (Sigma, Germany) 
8% and 10% SDS PAGE (Acryl amide; Roth, Germany) 
Bradford assay buffer (Biorad Laboratories, Germany) 
Nitrocellulose membrane (Millipore, Germany) 
ECL detection kit (Amersham Biosciences, Germany) 
ECL hyperfilm (Amersham Biosciences, Germany) 
2.1.4 Antibody  
Anti- Survivin (Novus Biologicals, USA, NB 500-201) 
Anti-HSC 70 (Santa Cruz Biotechnology, CA, USA, sc-7298) 
Anti-hnRNPA2/B1 (Santa Cruz Biotechnology, CA, USA, sc-10036)  
Anti-Casein Kinase 1α (Santa Cruz Biotechnology, CA, USA, sc-6477)  
Anti-O-GlcNAc (Covance research products, USA, MMS-248R) 
Anti- Calreticulin (sigma-aldrich, C-4606) 
Anti- Prohibitin (Santa Cruz Biotechnology, CA, USA, sc-18196) 
Anti- ETO (Santa Cruz Biotechnology, CA, USA, sc-9737 and sc-9737x) 
Anti- hnRNPH/F (Santa Cruz Biotechnology, CA, USA, sc-15387) 
Anti- β-tubulin (Santa Cruz Biotechnology, CA, USA, sc-9104) 
2.1.5 Plasmid constructs and transient transfections 
 
PINCO AML1/ETO retroviral plasmid (kindly provided by Dr.Pellicci) 
pLuc 1430c-survivin promoter luciferase construct (kindly provided by Dr. 
Altieri) 
GFP (Invitrogen, Germany) 
Nucleofector kit (AMAXA, Cologne, Germany) 
2.1.6 Chemicals  
 
Acetonitrile (Sigma Aldirch, USA) 
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Acetic acid (Merck, Darmstadt, Germany) 
Ammonium bicarbonate (Sigma, USA) 
Dimethyl sulfoxide (DMSO) (Sigma, USA) 
Ethanol (Merck, Darmstadt, Germany) 
Formaldehyde (Merck, Darmstadt, Germany) 
Glycine (ICN Bio-medicals) 
Isopropanol (Merck, Darmsadt, Germany) 
Methanol (Merck, Darmstadt, Germany) 
Propidium iodide (Sigma, USA) 
Silver nitrate (Merck, Darmsadt, Germany) 
Sodium carbonate ( Merck, Darmstadt, Germany) 
Sodium thiosulfate (Merck, Darmstadt, Germany) 
Sodium dodecyl sulphate (SDS) (Sigma, USA) 
Trifluoroacetic acid (TFA) (Merck) 
Triton X-100 (Sigma, USA) 
Zinc sulphate (Sigma, USA) 
 
2.2 Methods 
2.2.1 AML patient samples 
 
42 bone marrow samples of the following AML subtypes were used in this 
investigation: t(8;21) (n=6), t(15;17) (n=7), inv(16) (n=6), 11q23 (MLL/PTD) 
(n=6), normal karyotype (n=11), complex aberrant karyotype (n=6). The 
studies were conducted according to the rules of the local ethical committee 
and the revised Helsinki protocol. Written informed consent from the patients 
was obtained. At the time each AML patient was diagnosed, mononuclear 
cells from the bone marrow aspirate with more than 90% blast cells were 
purified by Ficoll density centrifugation. The healthy bone marrow cells were 
purchased from stem cell technologies (cell systems Biotechnologie Vertrieb 
GmbH). CD34+ cells were isolated from the remains of leukapheresis 
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products and sorted by MACS by a positive selection using CD34+ progenitor 
cell isolation kit, human, Militeny biotech. 
2.2.2 Two dimensional gel electrophoresis and DIGE 
 
Five master gels with gradients pH 3-10 and 4-7 were made from each 
cytogenetic group : t(8;21) (4 gels pH 3-10 and 1 gel pH 4-7), t(15;17) (2 gels 
pH 3-10 and 3 gels pH 4-7), Inv(16) (3 gels pH 4-7 and 2 gels pH 3-10 ), 
complex aberrant karyotype ( 4 gels pH 3-10), 11q23 (3 gels pH3-10) and 
normal karyotype( 10 gels pH 3-10 and 3 gels pH 4-7), healthy bone marrow ( 
2 gels pH 3-10) and CD34+ cells (2 gels pH 4-7 and 1 gel pH 3-10). In order 
to control the gel to gel variability in staining and running conditions between 
cytogentic groups, four patient samples belonging to different cytogenetic 
groups were processed together. 300µgs of protein in all the experiments were 
subjected to IEF and a minimum of four 2D gels were run and stained 
together. 107 cells from each patient sample were carefully thawed and 
dissolved in 10ml of IMDM, supplemented with 20% FCS, heparin 200IE per 
ml, and DNAse. After centrifugation the pellet was lysed in a sample buffer 
containing 7M urea, 2M thiourea, 4%(w/v), 3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonic acid (CHAPS), and 1% (w/v) DTT for 
all silver stained gels. For DIGE experiments, samples were dissolved in a 
DIGE compatible lysis buffer containing 25 mM Tris, 4% CHAPS (w/v), 8M 
urea, and 2M thiourea. Protein labelling with cyanine dyes (Cy3 or Cy5) was 
performed according to the manufacturer’s (Amersham biosciences) 
instructions. 300µgs and 50µgs of protein respectively were used for all silver 
stained gels and DIGE experiments, respectively. The proteins were subjected 
to Isoelectric focusing for the first dimension of protein separation which was 
performed with a Multiphore II electrophoresis system (Amersham 
Biosciences, Piscataway, NJ). Immobiline Dry IPG strips (for DIGE: 24 cm, 
pH 4–7 linear IPG strips, Amersham Biosciences) were rehydrated overnight 
with the sample/rehydration buffer mixture. For silver staining 18cm, pH 3-10 
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and 4-7 linear IPG strips were directly rehydrated with the sample buffer. The 
strips were subjected to electrophoresis using a ramping IPG strip (200–8000 
V) focusing algorithm. After the isoelectric focusing, the gel strips were 
electrophoresed in vertical SDS-PAGE gels containing 12.5% acrylamide. The 
Cy2, Cy3, Cy5 labelled gels were scanned at 473nm, 532nm and 635nm 
excitation laser filter using laser based FUJI scanner (Fluor imager, FLA 5100 
version 1.0). 
2.2.3 Statistical analysis 
 
For evaluating the mean expression volumes (mean intensity values) of ingel 
spots, gels were matched from within a particular cytogentic groups and from 
other cytogenetic groups. ProteomWeaver software, version 2.0, Definiens 
AG, Munich, was used. Standard statistical methods were used to analyse the 
plots includes mean, standard deviation and coefficient of variation calculated 
as standard deviation/mean. Changes in spot intensity was considered 
significant where the average normalized volume altered by greater than 1.5-
fold between samples. P values were calculated from the student’s t-test by 
comparing the means of two different AML subtypes (expressed as the 
standard deviation of the difference between the two means).  
2.2.4 MALDI-TOF mass spectrometry 
 
Spots were excised manually from silver-stained and for fluorescent gels an 
automatic spot picker (Bruker daltonic) was used. Gel pieces were rehydrated 
in 50 ng/µl trypsin (Promega, Southampton, UK) in 25 mM ammonium 
bicarbonate on ice for 20 min. The gel pieces were incubated at 37 °C 
overnight. The speedVac dried peptides were dissolved in 5µl of 20% (v/v) 
acetonitrile, 0.1% (v/v) trifluoroacetic acid, sonicated for 5 min, and spotted 
along with 0.5 µl of 10 mg/ml -cyano 4-hydroxycinnamic acid (CHCA, 
Sigma) in 50% (v/v) acetonitrile, 0.1% (v/v) trifluoroacetic acid onto a 
MALDI target plate for analysis. The mass determinations were performed on 
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the MALDI TOF/TOF mass spectrometer (Applied Biosystems; AB4700) 
operating in reflectron mode and with ion source pressure 0.5 µTorr. After a 
400-ns time-delayed ion extraction period, the ions were accelerated to 20 kV 
for time of flight (TOF) mass spectrometric analysis. A total of 600-1000 laser 
shots were acquired and signal averaged. The Data were analyzed through 
GPS explorer (AB 4700 inc., USA) using a Swiss/Prot protein database for 
Mascot search assuming 1) monoisotopic peptide masses, 2) cysteine 
carbamidomethylation, 3) variable oxidation of methionine, 4) a maximum of 
one missed trypsin cleavage, and 5) a mass accuracy of 60 ppm or better, 
minimum Signal/Noise 45. The four high intense peaks were selected in a 
range between m/z 1500 to 2500 for MS-MS peptide sequencing in an 
interpretation method. A molecular weight search (MOWSE) score >53 was 
assumed to indicate a significant match. For detailed MS and MS-MS spectra 
analysis, the MS spectra of potential proteins to be dissected for possible 
PTMs were imported to the peak explorer software, and the MS-MS spectra 
were imported and sequenced in the data explorer software. The 
posttranslational modifications were included as a variable modification, and 
searched by MASCOT database. Further to narrow down MASCOT search 
we created separate path for calreticulin, hnRNPH1 and hnRNPA2/B1 in 
MSDB. The modified peptides was reanalysed in a peak explorer from their 
corresponding MS spectra. For this analysis we used all the MS spectra of 
Calreticulin, hnRNPA2/B1 and hnRNP H identified from different subgroups. 
The sample corresponding to hnRNPH1 was fractionated by Nano LC 
(Dionex) using 500 µm i.d. x 5mm, C18 reverse phase column with a flow 
rate of 200nl/min. 
2.2.5 Transient transfections using LipofectAMINE plus and reporter 
assays firefly and renilla luciferase  
 
293T (1-2x 104)  cells were seeded in a 24 well plate in 0.5 ml of complete 
growth medium 24h before transfection and grown to 50-80% confluence. A 
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total of 0.4µg of various plasmids were cotransfected that include, PINCO-
GFP vector, PINCO-AML1-ETO retroviral construct or pCDNA3-AML1-
ETO, AML1b plasmid (Grignani et al., 1998) and pCDNA3-C/EBPα were 
mixed with 20µl of serum free media and incubated for 15 minutes. 1µl 
LipofectAMINE plus reagent (Invitrogen, Gmbh, Karlsruhe, Germany) was 
mixed with the 24µl serum free media and combined with the DNA-media 
complex and incubated for additional 15 minutes. After 3-4 h serum starvation 
of cells in a serum free medium at 37 °C, the DNA-liposome complex was 
replaced with complete medium and cultivated for an additional 24h at 37 °C. 
Cells were washed in PBS, pH 7.4, solubilized in 50µl of lysis buffer 
(Promega) and scraped with a rubber policeman, and then 10µl aliquots of the 
supernatant were mixed with 50µl of luciferase assay reagents (Promega). 
Firefly luciferase activities from the constructs of pLUC survivin promoter 
construct pLuc-1430c (Li and Altieri, 1999) and p(C/EBP)2TK and renilla 
luciferase activity from the internal control plasmid PRL-null were 
determined using the dual Luciferase Reporter Assay system (Promega). 
Firefly luciferase activities were normalized to renilla luciferase values of 
PRL-null (Behre et al., 1999) analysed on a Lumat luminometer (LB9510). 
Results are given as means +/- SEM of at least 4 independent experiments. 
Following DNA concentrations of the reporter constructs and expression 
plasmids were used for lipofectAMINE plus transfections, 0.1µg of pCDNA3-
human C/EBPα, AML1-ETO, AML1b, pLuc Survivin, p(C/EBP)2TK each; 
0.02µg of the internal control plasmid PRL-NULL and the same 
concentrations of the empty expression vector were used as a control 
respectively. 1µg and 0.5µg of survivin shRNA was used for all the 
experiments performed. 
2.2.6 shRNA and flow cytometric analysis  
 
Human CD34+ hematopoietic cells were isolated from human cord blood 
cells. Briefly, CB was collected on delivery with informed consent. The blood 
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was diluted with MACS-buffer 1:5 and mononuclear cells were isolated by 
lymphocyte separation medium (LSM 1077, J 15-004, PAA). The lymphocyte 
ring was collected, transferred to a new tube and washed with MACS-buffer. 
Pellets were dissolved in 300µl MACS buffer and 100µl FCR blocking 
reagent and incubated for 10min. at 4oC. 100µl of CD34 microbeads were 
added and incubated for 30 minutes at 4oC. The cells were washed and CD34+ 
cells were sorted by MACS system (Miltenyi Biotec). More than 70% of the 
cells were required to express the CD34 antigen. An aliquot containing 5×105 
CD34+ cells was cultured initially for 12 hours in IMDM with 10% heat-
inactivated FBS, 50 ng/ml Flt3-ligand (Flt3-L), 50 ng/ml stem cell factor 
(SCF), 50 ng/ml thrombopoietin (TPO), 10 U/ml penicillin/streptomycin and 2 
mM L-glutamine. The cells were transfected with survivin shRNA, 1µg, 
0.5µg and 0.1µg (cat. No. RHS1764-97182020, Open Biosystems). The short 
hairpin shRNA is cloned into retroviral backbone named as pSM2C (pSHAG-
MAGIC2) with the following sequence primers U6 5’ TGT GGA AAG GAC 
GAA ACA CC. Control shRNA, 500ng (RHS1707 Open Biosystems) using 
AMAXA nucleofection technology (AMAXA, Gmbh, Cologne, Germany). A 
5 µg portion of plasmid DNA constructs was used for each transfection and 
the transfection efficiency was analyzed using a plasmid with eGFP marker 
(2 µg). Nucleofector solution kits VPA-1003 was used for CD34+ cells and 
VCA-1003 for U937 and Kasumi1 with nucleofection programs U-08 (for 
CD34+) and V-01(for U937) and T-020 (for Kasumi 1). The voltages are 
automatically adjusted according to the program and are essentially 110 V AC 
with a frequency of 50–60 Hz and a power consumption of 16 VA/fuse as 
described by the manufacturer. Transfection efficiency was analyzed using a 
plasmid with eGFP marker (2 µg). After 12 hours, the cells were spin down 
and replaced with new media RPMI plus 10% FCS without cytokines. 1x106 
Kasumi1 cells were transfected with survivin shRNA and control shRNA as 
described above. After 72 hours, FACS analysis was performed for CD34+ 
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cells for CD15 expression on a flowcytometer (Becton Dickinson) using FITC 
labeled CD15 antibodies (55401, BD Pharmingen) and IgG-FITC (555742, 
BD Pharmingen) as an isotype control.  
2.2.7 Quantitative real-time PCR analysis 
 
CD34+ cells were transfected with pCDNA3-C/EBPα, PINCO-GFP vector 
alone and PINCO AML1-ETO retroviral construct and after 24hours cells 
were transfected with survivin shRNA and control shRNA and incubated for 
another 48 hours. RNA was isolation by TRIZOL method (Invitrogen, 
Germany) followed by cDNA synthesis using standard conditions. Equal 
amounts of cDNA were used and gene expression was quantified by real-time 
quantitative RT-PCR in a Rotor-Gene RG-3000 (Corbett Research, Germany) 
using a SYBR Green kit (Qiagen, Germany). The methods were employed 
according to the manufacturer's protocol. Following PCR primer sequences 
was used for Myeloperoxidase, MPO, expression,  5`-TCG GTA CCC ATG 
TCA GGA AG-3` (Forward) and 5`-CCA GGT TCA ATG CAG GAA GT-3` 
(Reverse). To determine the relative expression level of each sample, GAPDH 
expression levels were measured as internal controls. The delta ct value (∆ct) 
was calculated from the given ct value by the formula: ∆ct = (ct sample – ct 
control). The fold change was calculated as (= 2-∆ct).  
2.2.8 Immunoblot analysis 
 
Patient samples were lysed in a lysis buffer containing 50mM Tris pH 8.0, 
0.5% Triton X-100, 0.5% Nonidet P-40, 150mM Nacl, 5mM EDTA, 0.5% 
sodium deoxycholate, 1% protease inhibitor and phosphatase inhibitor 
cocktail 1 and 2 (Sigma). Protein concentration was determined by the 
Bradford assay (Bio Rad Laboratories GmbH, Germany). Protein (60µg) were 
resolved on 6-10% SDS polyacrylamide gel electrophoresis, transferred onto 
Immobilon-P (Millipore, USA), blocked in 5% nonfat dry milk in TBS with 
0.02% Tween 20 for 1 hour at room temperature and then incubated with 
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primary antibodies, 1:500, in TBS-T ( with 2.5% nonfat dry milk) overnight at 
4oC. Anti calreticulin was used in a primary dilution of 1:50,000. A secondary 
incubation in a dilution range 1:1000 and 1:100,000 (for calreticulin) were 
followed by using donkey anti rabbit IgG-HRP (Amersham Biosciences, UK, 
catalog no.NA934) and 1:5000 dilutions for donkey anti goat IgG-HRP (Santa 
Cruz biotechnology, catalog no. sc-2056). For O-GlcNAc (β-O-linked N-
acetyl glucosamine detection, membranes were equilibrated in methanol and 
air dried. The dry membrane was incubated with a 1:1000 dilution of anti- O-
GlcNAc antibody in 1% BSA/ PBS with 0.01% Tween 20 for 2 hours and 
then washed 3 times in PBS. To demonstrate O-GlcNAc specific 
immunoreactivity, 10 mM GlcNAc was added during the primary incubation 
(Comer et al., 2001). The membrane was incubated with HRP conjugated goat 
anti-mouse (1.5000) in PBST for 1 h. After thorough washings membranes 
were developed using ECL reagents (Amersham Biosciences). For re-probing 
the blots, stripping solution, 100mM β mercaptoethanol, 2% SDS and 
62.5mM Tris-cl pH 6.8 was used. Briefly, membranes were rinsed in 
methanol for few seconds and washed 3 times in TBST and incubated in 
stripping solution for 40 minutes at 58oC under rotation. After the incubation 
membrane was washed 4 times in TBST and blocked fro 2hours in 1% BSA. 
2.2.9  Electrophoretic Mobility-Shift Assay (EMSA) 
 
EMSA was performed by using a non radioactive DIG Shift Kit (Roche, Cat. 
No. 1635 352). Complementary oligonucleotides were annealed at 95oC and 
labelling was performed according to manufacturer recommendations. 
Following sequence of the human survivin promoter was used (-1316) 5'-CTG 
GTG TGG TGC ATG CCT T-3'(-1297); and the sequence of the Sp1 binding 
site used for non specific competition from the survivin promoter 5'-ATT 
CGA TCG GGG CGG GGC CAG-3'. Nuclear extracts (20 µg) were incubated 
with 15 fmol/µL of double-stranded oligonucleotide in a 20µL of final 
reaction mixture as recommended by the manufacturer. Cells (2-5 x 107) were 
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harvested, pelleted and washed 2X in 5ml of ice cold phosphate-buffered 
saline (PBS), and the cells were resuspended in I ml of cold PBS and 
centrifuged at 2000rpm for 5 minutes. The following procedures were then 
carried out at 4°C. Cells were resuspended in 1 volume cold buffer A (20 mM 
Tris [pH 8.0], 3 mM MgCl2, 10 mM NaCl, 0.2M EDTA, 1 mM DTT, and 
0.1% NP40, 10% Glycerol supplemented with protease and phosphatase 
inhibitors) and were allowed to swell on ice for 15 minutes with shaking in 
between. The cells were centrifuged at 2000 rpm for 5 minutes and the 
supernatant fraction was discarded. The pellet was resuspended in 2 pellet 
volume of cold buffer C (20 mM Tris [pH 8.0], 20% glycerol, 400 mM NaCl, 
0.2 mM EDTA, 1 mM DTT, protease and phosphatase inhibitors) and 
incubated on ice for 10 minutes. Tubes were repeatedly freeze and thaw in 
liquid nitrogen and 37oC water bath and finally centrifuged at 13000 rpm for 
20minutes and the supernatant fraction (containing DNA binding proteins) 
was stored at -80°C. Protein concentrations were measured by Bio-Rad protein 
assay reagent (catalog no. 500-0006; Bio-Rad, Hercules, CA). For supershift 
experiments, anti- ETO goat polyclonal (catalog no. sc-9737x; Santa Cruz 
Biotechnology), anti-AML1 goat polyclonal (catalog no. sc-8564x; Santa 
Cruz Biotechnology) respectively, were added and further incubated for 30 
minutes. 
3 Results 
 
3.1 Mass spectrometry based identification of proteins from 
different AML cytogentic groups  
 
This investigation was performed on 42 AML patients belonging to different 
cytogenetic groups. A prior written consent was obtained from each patient. 
The patients used in the study with their cytogenetic characteristic are given 
(Table 2). Patients with the MLL (11q23) translocation has been characterised 
as a specific subtype of AML (Haferlach et al., 2004). The classification of 
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patients is in accordance with the latest WHO classification of AML where 
cytogenetics abnormalities have been used as a major criterion. The proteins 
were identified by MALDI-TOF Tandem MS (MS/MS) analysis. Four 
peptides (ions) from each MS spectra of a given identified protein were 
sequenced by MS/MS to determine the amino acid sequence of peptides. This 
increases the confidence of the identification of a given protein. 2D gels of 
patient samples from each subtype including a normal bone marrow and 
CD34+ cells are shown (Figure 11). From the silver stained 2D gel of each 
patient all the visible spots were cut for protein identification. These include, 
340, 300, 372, 551, 854 and 203 spots from t(8;21), Inv(16), t(15;17), 
complex aberrant karyotype (here after CK), normal karyotype (here after 
NK) and 11q23 patients respectively. All the spots were analysed and 
processed for mass spectrometry based identification. This analysis leads to 
the identification of 32, 37, 32, 55, 60 and 24 proteins, respectively (Table 4). 
These proteins were ranked as identified with high confidence with a 
confirmation from MS/MS sequences of minimum 4 peptides, as discussed 
previously, for most of these proteins excluding a number of false positives. 
Interestingly, among the 240 proteins identified, 11, 17, 11, 20, 18 and 8 
proteins showed differential expression which means a specific expression 
from each of the cytogenetic group, t(8;21), inv(16), t(15;17), NK, CK and 
MLL, respectively. This represents 35% of all identified proteome (Table 3). 
Interestingly, the statistics points towards the fact that each cytogenetic 
translocation contributes significantly to the altered proteome.  
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No. Sex FAB Karyotype FLT3 
1 M M2 46XY, t(8;21)(q22;q22)
2 M M2 46XY, t(8;21)(q22;q22)
3         F M2 46XX, t(8;12;21)(q22;p13;q22)      FLT3-LM+
4 M M2 46XY, t(8;21)(q22;q22)
5 M               M2                        46XY, t(8;21)(q22;q22)
6         F                M2                        46XX, t(8;21)(q22;q22) 
7     F M3 46XX, t(15;17)(q22;q21)
8 M      M3v 46XY, t(15;17)(p22;q21)
9       M M3v 46XY, t(15;17)(q22;q21),                 
10 M M3 46XY, t(15;17)(q22;q21)
11 F                M3                        46XX, t(15;17)(q22;q21)
12 F                M3                        46XX, t(15;17)(q22;q21)
13 M               M3                        46XY, t(15;17)(q22;q21)
14 F                M4                        46XX, Inv(16)(p13;q22)
15       M               M4                        46XY, Inv(16)(p13;q22)
16 M M4Eo                    46XY, inv (16)(p13;q22)
17 M M4Eo 46XY, inv (16)(p13; q22)
18 F M4Eo 46XX, inv(16) (p13;q22)
19 F M4Eo 46XX, inv(16) (p13;q22)
Patients with balanced chromosomal translocations
Patients with complex abberant Karyotype
No. Sex FAB Karyotype
20 M M6 50XY+X, t(8;9;11)(q12;p24, p12)
21 F   M2 46XX, inv (3) (q21; q26) (20)46XX (4)
22 F    M1 47XX, t(5;16)(q11;p12),del(9)(q11)(11)
23 M M1 47XY+13
24 F             M1 42XX, der(1)t(1;6)(p11;q11),del(1)                                  
25 F               M1 47-51,XX, -3, der(5)t(3;5)(q21;q13)
Patients with MLL translocations
No. Sex FAB Karyotype
26 M t-AML 46XY,t(11;22)(q23;q12)
27 M M4 46XY,t(11;22)(q23;q12)
28 F - 46XX,t(4;11)(q21;q23)
29 F M4 46XX,t(11;19)(q23;p13.1)
30 M M5a 46XY,t(9;11)(p22;q23)
31 F M5a 46XX,t(9;11)(p22;q23)
Patients with a normal karyotype
N0. Sex FAB Karyotype FLT3 
32          M M4 46XX,                                                    FLT 3-LM+
33 M M5a 46XY
34 M M4 46XY
35 M M4 46XY
36 M M2 46XY CKIT d816+ FLT3 LM+ 
37 M M2 46XY
38 M M2 46XY
39 M M2 46XY
40 M M2 46XY
41 M M1 46XY
42 M M2 46XY
M, male; F, female, FAB, French-American-British classification; MLL, mixed lymphocyte lineage gene
Table 2. Cytogenetic and morphological characteristics of patients used in the study.  
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Figure 11. 2D gel images of AML patients with cytogenetic abnormalities. Whole cell 
lysates from patient samples, NBM and CD34+ cells were urea lysed (described in material 
and methods). In the first dimension 300µg of soluble proteins were ultracentrifuged and 
separated on immobilineTM dry strips pH 3-10 (Amersham Biosciences) by isoelectric 
focusing (IEF) which allows the separation of proteins on the basis of their respective 
isoelectric point (pI). Proteins were then resolved in the second dimension using 12% SDS 
PAGE on the basis of their relative size and molecular weight. 2D gels were silver stained 
to visualize the protein spots. All the visible spots were cut manually (as discussed in 
results) for the MS analysis. 
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Table 3. Proteins identified as differential targets of cytogenetic groups 
                                                                                                                                                                                                                                  
CK                                                                t(8;21)                                                            
 
Hepatoma derived growth factor (HDGF)                                 Transcriptional repressor NF-X1                                
hnRNP Do ( AU rich element R)                                               Transcription elongation factor IIS                             
Alpha-1-antitrypsin precursor (alpha-1 protease)                      FUSE binding protein 2                                              
Adenosine deaminase                                                                 hnRNPG 
B-cell lymphoma/ leukemia IIA                                                 Myeloid cell nuclear differentiation antigen               
Diacylglycerol kinase, gamma                                                   Nucleophosmin 
ERp29 precursor                                                                        Ras related protein RAB3                                            
Endoplasmic precursor(GRP94                                                 Sorcin 
Hypothetical Zinc finger protein KIAA0628                            Transgelin 2 
hn RNPK                                                                                    BMP-3b                                                                       
Alpha -2HS-glycoprotein precursor                                          Casein kinase II       
Mitogen activated protein kinase-kinase                                   Apoptosis inhibitor survivin 
Sentrin/SUMO specific protease SENP2                         
Splicing factor, proline and glutamine rich                     
Sorting nexin II                                                                
Splice factor 3B subunit 5                                                
Proline rich protein 4 precursor                                      
Ras related protein Rab-8A                                            
Ruv B-like 2                                                                    
Splice factor, arginine / serine rich 3                              
 
                                                     
MLL                                                             t(15;17) 
 
HSP70.1                                                                                       Splicing factor DNA binding p52/100                              
Zyxin 2                                                                                         Ring finger protein 16                                                       
L-plastin                                                                                       Similar to ATP binding protein  ( associated with cell differentiation)               
Lactotransferrin protein                                                               Antithrombin 
Phosphatidylethanolamine binding protein                                 BCL-6 corepressor                                                           
Stress induced phosphoprotein 1                                                 Core binding factor beta                                                     
Ubiquitin tropomodulin (U-T mod)                                            Epithelial glycoprotein antigen (GA733-2 precursor )       
52 kda phosphoprotein lymphocyte                                            Guanine nucleotide binding protein G(q)                           
                                                                                                     Myeloperoxidase splice variant H17                                  
                                                                                                     Phospholipase D2                                                            
                                                                                                     Plasminogen related protein A        
                                                                                                     A 20 binding inhibitor of NF-κB activation 2                    
 
Inv(16)                                                                NK                                                          
 
ATP dependant DNA helicase II                                                          Cellular glutathione peroxidase                                        
Bone marrow zinc finger protein 255                                                   Cargo selectin protein                                                       
Chaperonin, mitochondrial matrix protein P1                                      Casein kinase 1, alpha isoform                                         
HSPA5                                                                                                  Chromatin assembly factor 1 subunit C                          
Transcription factor MafK                                                                    CDC 2-related protein kinase                                                            
HSP90 alpha                                                                                         Cathepsin D                                                                     
Leukocyte derived neural aminopeptidase                                           UBE3B variant 1                                                             
Myeloblastin precursor (leukocyte proteinase 3)                                 Laminin binding protein                                                  
Melanoma associated antigen B3 (MAGE-B3)                                    Zeta sarcoglycan                                                              
Nucleolar transcription factor 1 (UBF1)                                              PDZ-LIM protein 1                                                         
Prolyl 4-hydroxylase, v-erb                                                                  Similar to nucleolin                                                         
Plectin                                                                                                   T-complex protein 1 beta subunit                                   
Serine (or cysteine) proteinase inhibitor                                               Transformation sensitive protein 1EF SSP 3521            
Tranlational control tumor protein(TCTP                                            Transcription factor MAX, chain B                                 
KIAA1937                                                                                            MRP-14                                                                           
KIAA0141 similar gene product                                                          Nuclear receptor ROR alpha                                            
                                                                                                             Apoptosis inhibitor survivin                                             
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 Table 4. Proteins identified by MALDI-TOF mass spectrometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proteins identified from t(8;21) patients 
 
                                                                                  Mowse     Theoretical    Theoretical                               Sequence              MSMS
 Protein name                                                          Score             pI               Mr[Da]          Accessiona          coverage(%)        Matches
 
ATP synthase beta chain mitochondrial                    277                5.26           56525             P06576                 35                         3 
Annexin A1                                                                119                6.64           38787             P04083                 28                        2 
Actin cytoplasmic 2, gamma actin                             87                 5.31            42108             P02571                 18                        3 
BMP-3b                                                                      190                9.58           53149             P55107                 27                        3 
Casein kinase II                                                          57                  8.65           41358             P19784                 34 
Calreticulin precursor                                                 95                  4.29           48283             P27797                 50                        2 
Chaperonon GroEL precursor                                    117                5.70           61187             P10809                 40    
DEAD-box protein 4                                                  68                  5.38           76571             Q9NQ10               21                        
FUSE binding protein 2                                             73                  8.0             72721             Q92945                 25                        1 
Flavoprotein alpha subunit                                         162                8.62           35400             P13804                 46                        1 
GRP 78                                                                       172                5.07           72315             P11021                 40                        2 
GAPHD                                                                      230                8.85           36070             P04406                 30                        2 
Gluthione transferase omega                                      66                  6.23           27833             P78417                 26                        1 
HnRNPA2/B1                                                            187                 8.97           37464             P22626                 42                        2          
hnRNP F                                                                     278                5.38           45985             P52597                 41                        2 
hnRNPG                                                                     58                  10              42306             P38159                  27 
Heat shock cognate 71 KDa                                       79                  5.37           71082             P11142                 15                        1 
60KDa heat shock protein, mitochondrial                 225                5.70           61187             P10809                 23                        3           
Lamin B1                                                                   388                 5.11           66522             P20700                 37                        3 
Leukocyte elastase inhibitor(LEI)                              77                  5.90           42742             P30740                 23 
Myeloid cell nuclear differentiation antigen              70                   9.77          46092             P41218                 24 
Nucleophosmin                                                          170                 4.64           32726             P06748                 25                        2  
Prohibitin                                                                    144                 5.57          29843             P35232                 40                       
Ras related protein RAB3                                           68                  6.92           22227             P36409                 28                        1 
Rho-GDP dissociation inhibitor 2                              68                   5.73          21602             P52566                 23 
Sorcin                                                                          82                   5.3            21947             P30626                 31                        1 
Stathmin (OP18)                                                         105                 5.77          17161             P16946                 44                        1 
Superoxide dismutase (Mn)                                       162                  8.35          24878            P04179                  34                        2          
Transgelin 2                                                               181                  8.41          22548             P37802                 54                        2 
Tropomyosin alpha 3 chain                                        224                  4.68          32856            P06753                 20                        2 
Transcriptional repressor NF-X1                               60                    8.47          128656          Q12986                 16                        1  
Transcription elongation factor IIS                            64                    8.65           33975            P23193                 35 
       
 
Proteins identified from 11q23 patients 
 
Actin cytoplasmic 1 beta                                           378                   5.29          42052            P60709                24                         4 
Calnexin precursor                                                    100                   4.47          67982            P27824                23                         1 
Delta 3,5-delta 2,4-dienoyl –CoA isomerase            67                     6.61          36314            Q13011                18                        1 
Destrin (actin depolymerising factor)                       66                     8.06          18950            P60981                25 
Gluthione S-transferase P                                          213                   5.44          23438            P09211                36                        3 
GAPHD                                                                     122                   8.58          36070            P04406                28                        1 
Hematopoietic lineage cell specific protein               68                    4.74          54079            P14307                24                        1 
hnRNP H                                                                   171                   5.89          49484            P31943                25                        2 
hnRNPA2/B1                                                            104                   8.97          37464             P22626               26                        1 
Heat shock cognate 71 KDa protein                         199                   5.37          71082             P11142                23                       1 
HSP70.1                                                                    78                     5.48          70294            O08107                28 
HSP 90 beta                                                               70                     4.97          83423            P08238                30                       2 
52 kda phosphoprotein lymphocyte specific            118                    4.69          37397            P33241                23                       1 
L-plastin                                                                    95                     5.20          70815             P13796                24                       1 
Lactotransferrin protein                                             80                     8.56          80170            P02788                24                       1 
Peroxiredoxin 2                                                          68                    5.66          22049             P32119                31                       1            
Phosphatidylethanolamine binding protein               227                   7.42          21027            P30086                43                       3      
Phosphoglycerate mutase                                          77                     6.75          28769            P18669                26 
Rho-GDP dissociation inhibitor 2                             261                   5.01          23031            P52566                60                       3 
Stress induced phosphoprotein 1                               83                     6.4            63227            P31948                18 
Tropomyosin alpha 3 chain                                       131                   4.68          32856            P06753                19                       1 
Ubiquitin carboxyl terminal hydrolase 14                 94                     5.20          56358            P54578                21 
Ubiquitin tropomodulin (U-T mod)                          59                      5.08          39741           Q9NYL6              16                      1 
 Zyxin 2                                                                      108                   6.22          62436           Q15942                18                      2 
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Proteins identified from Inv (16) 
 
Alpha enolase                                                                   91                 6.99             47350              P06733             44              3 
Abnormal spindle protein                                                100                9.0               107719           Q8IZT6             22              1 
Annexin 1                                                                        108                6.57             38918              P04083             43 
ATP synthase D chain mitochondrial                              115               5.22             18405               P30049            38 
ATP dependant DNA helicase II                                     71                 6.23              69717              P12956             24              1 
Bone marrow zinc finger protein 255                              65                 8.99             75063              Q9UID9            26 
BIP protein                                                                       76                 5.23             71002              Q9UK02           27 
Calreticulin precursor                                                      127                4.29             48283              P27797             29              1 
Calnexin precursor                                                           81                  4.5              67982               P27824            25               3 
C-myc promoter binding protein                                     243                7.01             47481              P06733            38               3 
Chaperonin, mitochondrial matrix protein P1                 80                  5.7               61187              P10909            20               1  
Ferratin light chain                                                           88                  5.51            19933               P02792            43 
Glutathione synthetase                                                    120                5.67             52523               P48637            41              1 
GRP 78                                                                            131                5.1               72402               P11021            27              3 
HSPA5                                                                             107                5.03             71082              P11021            40                     
HSP 90 beta                                                                     116                5.0               83423              P08238            27               3 
HSP90 alpha                                                                    215        ´       4.9              67982               P07900            26               3 
KIAA1937                                                                       70                  6.23             82191              Q96PV1          27 
KIAA0141 similar gene product                                     70                  7.24             56371              Q14154           20 
Leukocyte derived neural aminopeptidase                      72                  5.78             61412              Q8TD32          23 
Moesin                                                                             78                  6.08             62004               P26038           38 
Myeloblastin precursor (leukocyte proteinase 3)             63                 8.7               28245               P24158           30               2 
Monocyte/Neutrophil elastase inhibitor (LEI)                 68                 9.1               42829               P30740           26               1 
Melanoma associated antigen B3 (MAGE-B3)               62                  9.8              39326               O15480           32               1 
Nucleolar transcription factor 1 (UBF1)                          61                 5.6               89692               P17480            24 
Protein disulphide isomerase precursor                           105                4.76            57146               P30101            21               3 
Prolyl 4-hydroxylase, v-erb                                             76                  4.76            57480               P07237            26               1 
Plectin                                                                               65                 5.38             64921              Q15149            26              1 
Ribosomal protein L13A                                                  70                 6.98             18953              Q8N6Z1           43              1 
Serine (or cysteine) proteinase inhibitor                           80                 5.9              42829              Q4VAX4          27              1 
Signal recognition particle 54                                           77                 8.87            55718               P61011            21               1 
Tranlational control tumor protein(TCTP)                       65                 4.98            19696               P13693            20 
Thioredoxin like protein                                                   60                 4.8              32630               O43396            27 
Transcription factor MafK                                                61                 6.9              18158               O60675           19               1 
Vimentin                                                                           170               5.06             53579              P08670            23               3 
Valyl 1-t RNA synthetase                                                 80                5.10             105432            Q7TUID           21              1 
 
 
Proteins identified from complex aberrant karyotype 
 
Alpha -2HS-glycoprotein precursor                                74                   5.26               39193               P12763           22            1 
Annexin II type 1                                                             91                   8.60              38618                P27006           26 
Adenylate kinase isoenzyme                                           105                 5.38               22358               Q9Y6K8         40         
Annexin A1                                                                     212                 6.64                38787               P04083           39           3 
Alpha-1-antitrypsin precursor (alpha-1 protease)           71                   5.37               46878               P01009            19           1 
Alpha enolase                                                                  359                 6.99               47350                P06733           50           3 
Adenosine deaminase                                                     241                  5.63               41024                P00813           26           2 
ATP synthase alpha chain                                               83                   9.16               59828                P25705           27           1 
Actin cytoplasmic 1 beta                                                 110                 5.29               42052                P60709           25           1 
B-cell lymphoma/ leukemia IIA                                      71                  6.15                92565               Q9H165          19           1               
Chloride intracellular channel protein                             410                5.09                27248               O00299           56           4 
Calnexin precursor                                                          99                   4.47               67982                P27824           22           1 
Calreticulin                                                                      97                   4.29               48283                P27797           28           1 
Destrin (actin depolymerising factor)                              82                  8.06               18950                P60981            40       
DEAD box protein 4(VASA homolog)                           69                  5.67                80113               Q9NQ10          23                           
Delta 3,5-delta 2,4-dienoyl –CoA isomerase                  93                   6.61               36314                Q13011           26           2 
Diacylglycerol kinase, gamma                                        113                 6.29               90535                P49619            20 
ERp29 precursor                                                             79                   6.77               29032                 P30040           22           1 
Endoplasmic precursor(GRP94)                                     76                   4.76               92696                 P14625           27           1 
Glutathione synthetase                                                   132                  5.67               52523                 P48637           31           3 
Glutathione S-transferase P                                            282                 5.44                23438                P09211            55           2 
GRP 78                                                                           273                  5.07               72402                P11021            25           2              
Hematopoietic lineage cell specific protein                    81                   4.74               54079                P14317            20           1 
hnRNPF                                                                           86                  5.38                45985                P52597            22           2 
Hypothetical Zinc finger protein KIAA0628                  99                  8.46                63065               O75123            20          
hnRNP H                                                                         291                5.89                49484                P31943            23            2 
hn RNPK                                                                         117                 5.3                 51230                P61978            36            1 
Hepatoma derived growth factor (HDGF)                      65                   4.7                26886                 P51858            28             
hnRNP Do ( AU rich element R)                                   137                  7.6                 38581               Q14103            30            2 
hnRNP M                                                                       114                  8.94               77703                P52272            22             
Heat shock cognate 71Kda protein                                81                    5.37               71082                P11142            20            1 
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60KDa heat shock protein, mitochondrial                     276                5.70               61187                P10809             41 
Leukocyte elastase inhibitor(LEI)                                  81                  5.90              42829                 P30740            15 
Lamin B1                                                                        89                  5.11              66522                 P20700            20            
Moesin                                                                            85                  6.09              67761                 P26038            26 
Mitogen activated protein kinase-kinase                        94                  8.28              44716                 P45985            23           
Peroxiredoxin 6                                                              215                 6.02              25002                P30041            30             
Pyruvate kinase M1 isoenzyme                                      88                  7.95               58339                P14618            27          
Protein disulphide isomerase precursor                         313                4.76               57146                P30101            33 
Prohibitin                                                                       241                 5.57               29843                P35232            28 
Proline rich protein 4 precursor                                     60                   6.5                15088                Q16378            21 
Ras related protein Rab-8A                                           92                   9.15               23824                P61006            25 
Ruv B-like 2                                                                   63                  5.49               51296               Q9Y230            20 
Splice factor, arginine / serine rich 3                             75                   9.3                19546                P23152             27 
Stress 70 protein                                                             165                5.87              73920                P38646             27 
Splicing factor, proline and glutamine rich                    116                9.45              76216                P23246             25  
Sorting nexin II                                                               86                  6.61              30870              Q9Y5W9          36             
Splice factor 3B subunit 5                                               80                 5.89               10243               Q9BWJ5          41 
Splice factor, arginine/serine rich 1(SER1)                    136               9.12               27711                Q05519            33 
Sentrin/SUMP specific protease SENP2                        100                8.9                68637                Q9HC62          19 
Thioredoxin dependant peroxide reductase                    92                  7.67              28017                P30048            26             
Ubiquitin carboxyl terminal hydolase 14                       99                  5.20              56358                P54578             27 
Vimentin                                                                         186                5.06              53579                P08670            28 
Zinc finger protein 255                                                   90                  8.99              75063                Q9UID9           23 
 
 
Proteins identified from t (15;17) 
                                   
 
Alpha enolase                                                                    148              6.99           47350              P06733               23 
A 20 binding inhibitor of NF-κB activation 2                   65                6.06           48716              Q9BQR6            18 
Annexin A4                                                                        67               5.85           35751               P09525               20 
Annexin A1                                                                       215              6.64           38787               P04083               47 
Adenylate kinase isoenzyme 5                                          155              5.38           22358              Q9Y6K8             24 
Actin cytoplasmic 1                                                           101              5.31           42108               P02571              29 
Antithrombin                                                                      63               6.32           52604               P01008              22 
BIP protein                                                                         84               5.27           70920               Q9UK02            17 
BCL-6 corepressor                                                             80               6.06           192829             Q6W2J9            30 
Core binding factor beta                                                    55                6.23           21723               Q13951             20 
Chloride intracellular channel protein                               103              5.09           27248               O00299             41 
Calreticulin                                                                        330              4.29           48283               P27797              25 
Calnexin precursor                                                            92                4.47           67982               P27824              23 
Epithelial glycoprotein antigen (GA733-2 precursor)      66                8.14           34923               P16422              26 
GRP 78                                                                              198              5.07           71402               P11021              39 
Guanine nucleotide binding protein G(q)                          60                5.58           41726               P50148              26 
Growth arrest specific 6                                                     65                5.17           79680              Q14393             52 
hnRNP F                                                                            100               5.38          45985               P52597             22 
hnRNP H                                                                           194              5.89           49484               P31943              28               
Myeloperoxidase splice variant H17                                 67                9.19           83891               P05164             26 
Protein disulphide isomerase precursor                             99               4.76           57480               P07237              21               
Profilin IV                                                                          61               4.97           14481               Q8NHR9           35 
Phospholipase D2                                                              70                6.42           71620               Q86YQ7           25 
Plasminogen related protein A                                          65                8.44           10222               Q9UE70            44 
Rho-GDP dissociation inhibitor 3                                     100              5.45            25367              Q99819             25 
Ring finger protein 16                                                       70                6.62           54426               Q9Y577            20 
Similar to ATP binding protein-                                       66                5.56           22199               Q8TB70            27 
( associated with cell differentiation) 
Lamin A/C                                                                        103              6.57          74380                P02545              22 
Splicing factor DNA binding p52/100                             156              7.4              76216              P23246              17 
Stress 70 protein                                                               67                5.87           73920               P38646              29               
TOB 3                                                                               63                7.05           66237               Q9NVI7            25               
Vimentin                                                                           319              5.06           53579               P08670              36 
 
 
Proteins identified from Normal karyotype subtype 
 
 
Actin beta                                                                        196                 5.29             42052              P60700            23 
Annexin A1                                                                     142                 6.64             38787              P04083            35 
ATP synthase beta chain, mitochondrial                        145                 5.26             56525              P06576            50 
Alpha enolase                                                                  132                 6.99            47350               P06733            23 
Annexin 1                                                                        103                 7.77            35246               P04083            35 
Cargo selectin protein                                                      74                  5.67             41506              Q9BSO3          33 
C-myc promoter binding protein                                     188                 6.79            37862               P06733           19 
Cellular glutathione peroxidase                                       86                   6.15            22227               P07203           17 
Catalase                                                                            61                  6.95            59816               P04040            22            
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3.2 Proteins identified as distinguished targets of AML 
cytogenetic groups 
 
One of our aims of performing the proteomic screen of AML patients was to 
identify the proteins (diseased proteome) which could serve as distinguished 
markers for each AML cytogenetic subgroup. Our hypothesis was that since 
each cytogenetic group possesses different chromosomal fusions which may 
contribute differentially to the disease progression by altering the proteome 
differentially. Indeed, we could identify a set of proteins from each 
cytogenetic group including normal karyotype subtype which were 
 Casein kinase 1, alpha isoform                                        61                   9.59             39118               P48729            29 
Calreticulin                                                                      86                   4.29             48283               P27797            27                2   
Chromatin assembly factor 1 subunit C                         102                   4.74            47911               Q09028            24                3 
CDC 2-related protein kinase                                         70                     9.02            36005               Q9NYV4         20 
Cathepsin D                                                                    100                    6.1             45037               P07339            30 
Elongation factor 1 beta                                                 65                      4.5             24788                P24534           22 
UBE3B variant 1                                                            72                     8.45            124457             Q9BXZ4         18 
Elastase inhibitor                                                            79                     5.9              42829               P19957            24 
Ferritin light chain                                                          113                   5.65            16441               P02792            33                2 
Growth arrest specific 6 fragment                                  68                     8.84            79680              Q14393            52 
GRP 78                                                                           138                   5.07            72402               P11021            15                2 
Glutathione transferase omega                                       101                   6.23            27833               P78417            20                1 
hnRNP M                                                                        81                    8.84            77749               P52272            37  
hnRNP H1                                                                      108                   5.89            49484               P31943            27               1 
hn RNPA2/B1                                                                107                   8.67            36041               P22626            34                2 
hnRNP H´                                                                       94                    5.89            49517               P55795             29               1 
78KDa glucose related protein                                       88                    5.07            72402               P11021             36               2 
60KDa heat shock protein                                              161                  5.70            61187               P10809             50               2 
Laminin binding protein                                                 64                    4.84            31888               P17931            19                
Lamin C                                                                          78                    6.4              65153               P02545            25                
Lamin B1                                                                        138                  5.11            66522               P20700            20                1 
Myeloperoxidase ( 1 MYPA)                                         72                    5.28            11998               P05164            30 
MRP-14                                                                          68                    5.55            12770               P06702            20 
Nuclear receptor ROR alpha                                           60                   5.97            64306               P35398            15 
NADH-Ubiquinone oxidoreductase chain 2                   66                   8.59            39208               P03891             33 
Peptidyl-prolyl cis-trans  isomerase                               73                    5.36            64242              Q96AY3           39 
Protein disulphide isomerase  precursor                        183                  4.76            57480               P07237            16                3 
PDZ-LIM protein 1                                                        79                    6.56            36505               O00151           16 
Pyruvate kinase, M1 isoenzyme                                     117                 7.95            58339                P14618            23                2 
Peroxiredoxin 3 precursor                                              79                   7.67            28017                P32119            29 
Profilin, chain A                                                             83                   8.46            15014                P07737            25 
Prohibitin                                                                        122                 5.57            29843                P35233            40 
Probable thioredoxin peroxidase                                    136                 8.27            22324                P30044           44                2 
Phosphoglycerate kinase1                                              115                  8.3             44967                P00558            40 
Similar to lamin A/C                                                      139                 6.03            53222                P02545            40              
Similar to nucleolin                                                        80                   4.95            50977                P09405            17 
Stress 70 protein mitochondrial                                      63                  5.87             73920               P38646            17 
Stathmin (OP18)                                                             155                5.77             17161               P16949             29              1 
Splice factor, arginine/ serine rich 1                               113                9.12             27711               Q07955            22               2 
Similar to alpha fetoprotein                                            80                  5.97             48641               Q86YG0           28 
T-complex protein 1 beta subunit                                  125                 5.42             60153               P78371             50 
Transformation sensitive protein 1EF SSP 3521           110                 6.40             63227               P31948            26 
Tropomyosin TM30-PI fibroblast                                  67                  4.67             28367               P67936             22 
Tumor metastatic process associated protein                 78                  5.83             17309               P15531             31 
Transcription factor MAX, chain B                                66                  6.07             17073               1HLOB            45 
Ubiquitin carboxyl terminal hydrolase                           90                  5.2               56358               P54578             21 
Vimentin                                                                         603                5.06             53579               P08670             63            3 
Zeta sarcoglycan                                                             60                  7.59             21501               Q96LD1           23 
Zinc finger protein 255                                                   62                  8.99             75063               Q9UID9           21            1 
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distinguished feature of each AML subtype. These are the proteins which we 
identify specifically in each subtype. The details of these proteins including 
the S/T/Y phosphorylation sites for some of the proteins are given (Table 5). 
Full image 2D gels with the spot position where from these proteins were 
identified are given separately (Figure 12). Further of our interest was the 
expression pattern of myeloperoxidase variant H17, sorcin, B-cell CLL/ 
Lymphoma 11A and transcription factor MafK, identified specifically from 
t(15;17), t(8;21), CK and Inv(16), respectively. These proteins showed visibly 
distinct spot position on a 2DE gel. Even though we could reproduce the spot 
pattern on 2D gels from other subtypes including healthy bone marrow and 
human CD34+ cells. We could not identify these proteins from rest of other 
subtypes (Figure 13). As shown in the figure the corresponding spot position 
in the controlled gels, linear range pH 3-10, was consistently absent, even 
though the reproducibility in the spot pattern can be seen. These proteins 
owing to there unique expression in each subtype may serve as an important 
marker for diagnosis, prognosis and for designing subtype specific therapy.  
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Figure 12. Proteins identified as differential targets of cytogenetic groups. A silver stained 
full image 2D gel from 11q23 patient showing the spot where from 52KDa phophoprotein 
lymphocyte specific protein was identified (A). Similarly are shown the spots from 
t(15;17), Inv(16) patients where from core binding factor complex and translational control 
tumor protein (TCTP) was identified (B). Next, shown are the spot position for B-cell 
CLL/Lymphoma 11A, hnRNPDo and FUSE binding protein 2 (C). Theoretical pI and Mw 
are annotated on the image clip.  
 
 
 
 
FUSE binding protein 2
8.02
72721
pH3 pH10
Complex abberant Karyotype
t(8;21)
pH10
hnRNPK
hnRNDo
38581
5.45
hnRNPDo
pH3
B-cell CLL/ Lymphoma 11A
5.85
91841
 44
 
 
 
Figure 13. Differential expression of Myeloperoxidase variant H17, Sorcin, B-cell 
CLL/Lymphoma 11A and transcription factor MafK. Close-up sections of spots and a 
region on a 2D gel identified as  Myeloperoxidase variant H17, Sorcin, B-cell 
CLL/Lymphoma 11A and transcription factor MafK Identified specifically from t(15;17), 
t(8;21), CK and Inv(16) patients. A close-up comparison on a 2D gel pattern observed 
between other subtypes, CD34+ and healthy bone marrow are shown with reference spots 
used as a reference to manipulate the gels. As shown even though the reproducibility in the 
spot pattern can be observed, the specific protein spots are absent. All the identified 
proteins which showed specific expression are given in table 5. 
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3.3 Validation of differential expression of hnRNPA2/B1, casein 
kinase 1 alpha, prohibitin and HSC70  
 
Next we performed western blot analysis to confirm the identification of some 
of the therapeutically relevant proteins previously not reported in the context 
of AML cytogenetics. Casein kinase 1 alpha which we identified previously 
by mass spec from normal karyotype patients showed high and specific 
Table 5. Proteins identified as specific targets of Cytogenetic subgroups of AML
Proteins identified as specific targets of t(8;21)
Sequence S/T/Y
Protein name                          Accession       pI Coverage    Mr[Da] number   S/T/Y Phosphorylation site
Proteins identified as specific targets of t(15;17)
Proteins identified as specific targets of inv(16)
Nucleolar transcription factor 1(UBF1)          P17480        5.6    14    89692     T117         KHPDFPKKPLTPYFRFFM
Transcription factor MafK                              O60675   6.9    19   18158
Translational control tumor protein (TCTP)   P13693        4,9  20   19696
Hepatoma derived growth factor (HDGF)      P51858        4.7    28   26886       S132     DGDKKGNAEGSSDEEGKLVID
T200 PLPMEVEKNSTPSEPGSGRGP     
hnRNP Do (AU rich element R)                     Q14103        7.6    30   38581
B-cell CLL Lymphoma/Leukemia 11A            Q9H165      5.85  19  91841                 
Proteins identified as specific targets of complex abberant karyotype
Nuclear receptor ROR alpha P35398          5.97          15         64306
Growth arrest specific 6 Q14393 8.84          52        56369                 
Proteins identified as specific targets of AML patients with a normal karyotype
52 Kda phosphoprotein lymphocyte specific        P33241         4.69              23              37397
Stress induced phosphoprotein 1                         P31948  6.40              18              63227
Proteins identified as specific targets of 11q23 translocations
Myeloperoxidase splice variant H17 P05164 9.34 16             83891
Core binding factor  beta Q13951 6.23         20             21723    
Sorcin P30626           5.3            31         21947          
FUSE binding protein 2 Q92945           8.0            25         72721 
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expression from 3 different NK patient samples in Immunoblots (Figure 14a, 
panel A and B). We showed a differential expression of RNA binding protein 
hnRNPA2/B1 in NK patients (Panel C). This was further confirmed from 3 
different NK patients (Panel D). K562 erythroleukemic cell line lysate was 
used as a positive control for the expression of hnRNPA2/B1. In a similar 
analysis we further showed a differential expression of cell cycle protein 
prohibitin in t(8;21) and inv(16) patients which is consistent with the mass 
spec data (Panel E). Similarly, HSC 70 showed a very high expression in 
t(8;21), Inv(16), NK and CK patients in comparison to NBM and t(15;17) 
(Panel F). HL-60 cell line was used as a positive control and 3T3Li 
preadipocyte cell line as a negative control for HSC 70 expression.  
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Figure 14a. Validation of mass spec data by western blot. Western blot was performed to 
confirm the identification of some of the proteins from the whole cell lysates of different 
patient samples using specific antibodies. Panel A, it shows the expression of casein kinsae 
1 alpha which was further confirmed from two different patient samples belonging to 
normal karyotype (Panel B). The specific expression of hnRNP A2/B1 from NK patients 
was also confirmed (Panel C & D). Similarly, the differential expression of prohibitin 
(Panel E) and HSC 70 (Panel F) was confirmed from patient samples in line with the mass 
spec data. Calreticulin protein was used as a loading control for all cases. 
 
3.4 Survivin identified as a distinguished target of t(8;21) AML 
 
We identified a 16.5KDa apoptosis inhibitor protein (IAP) survivin as a 
specific target of t(8;21) AML from the proteomic screen. The identification 
of this protein was further confirmed by the western blot (Figure 14b). 
Because of the high therapeutic significance attributed to this protein, we 
characterized survivin both biologically and mechanistically.   
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Figure 14b. Western blot performed for the expression of survivin using different AML 
patient groups. Survivin expression was detected specifically in t(8;21) patient, thus, 
further confirming the mass spec data. 
 
3.5 AML1/ETO induces survivin expression  
 
Next we asked whether survivin which is a target AML1-ETO fusion protein 
could induce its expression. To test this hypothesis we used U937 cell line 
stably transfected with a cDNA of AML1-ETO cloned upstream of a 
tetracycline (tet)-responsive element. These cells express AML1-ETO after 
the withdrawal of tetracycline. We performed the cell lyses 48h after the 
withdrawl of tetracycline and performed a western blot. The results confirmed 
that U937 T-A/E cells express survivin following the expression of AML1-
ETO induced by the withdrawal of tetracycline while as no survivin 
expression was detected in the presence of tetracycline i.e, without AML1-
ETO. HL-60 whole cell lysate was used as a positive control for survivin 
expression (Fig. 15, panel A). We further confirmed this finding in HEK293T 
cells which has been extensively used to study AML1-ETO transcriptional 
mechanism and due to the gross overexpression off of the plasmids (Frank et 
al., 1999). We could show in 293T cells that AML1-ETO induces survivin 
expression as early as 24 hours post transfection which enhances subsequently 
with time (Fig. 15, B). Kasumi-1 cells which harbor endogenous AML1-ETO 
showed a very high expression of survivin as compared to NB4 cell line 
(Fig.15, panel E). HL60 cell line was used as a positive control for survivin 
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expression. This data confirms that AML1-ETO specifically activates survivin 
expression. The transfection efficiency reached by this method was 85% as 
confirmed by the expression of GFP plasmid (Fig. 15, C and D). The results 
strongly suggest that AML1-ETO specifically activates the survivin 
expression, whose expression is known to enhance with tumor and/or 
leukemic progression through albeit undefined mechanism. We specifically 
investigate the underlying mechanism leading to the induction of survivin by 
AML1-ETO.  
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Figure 15. Western blot anaylsis performed for survivin expression in tet off AML1/ETO 
inducible cell line. Data shows the expression of survivin was induced with the induction of 
AML1/ETO. HL60 cell line was used as a positive control for survivin expression 
(A).Whole cell lysates from 293T cells were separated on a 12% SDS PAGE and blotted 
with survivin antibody. The membrane was stripped off bound antibody and reprobed with 
anti calreticulin antibody to demonstrate equal loading of proteins (B). Transfection 
efficiency observed for 293T cells after the transfection of GFP plasmid (2µg) using 
lipofectAMINE plus was calculated by counting the cells first under normal light and then 
under fluorescent light using the same magnification and same field (panel C & D). The 
overall percentage of transfection efficiency reached by this method was 80%. Lysate from 
Kasumi-1, NB4 and HL60 was resolved on 12% gel to compare the levels of survivin 
expression which revealed a very high expression of survivin in Kasumi-1 cells; the lower 
panel shows the equal loading by stripping off the same blot. 
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3.5.1 AML1-ETO activates basal transcription of the survivin 
promotor 
 
To define the molecular mechanism of the survivin activation by AML1-
ETO, we analysed the sequence of the 5´ flanking region of the survivin gene 
using the TFsearch. The analysis revealed the presence of a single AML1 
binding site (TGTGGT), 1400bp upstream of the initiating ATG (Fig. 16, 
panel A). We performed a dual luciferase assay to elucidate whether AML1-
ETO could activate basal transcription of survivin promotor. Like AML1, 
AML1-ETO has been reported to act as a transcriptional activator (Rhoades 
et al., 1996). We transiently transfected 293T cells with a survivin promoter 
luciferase construct pLuc-1430 which has a single AML1 binding site and co-
transfected with an AML1 transcript variant, AML1b, alone or together with 
AML1-ETO and AML1-ETO alone. AML1b (Tanaka et al., 1995) is a 
putative transcriptional activator. Both AML1b and C/EBPα are thus 
supposed to have a negative effect on survivin activation as both supports 
myeloid differentiation. The results indeed demonstrate that AML1b has no 
significant effect on the activation of the basal transcription of survivin gene 
(Fig. 16 panel B, lane 2). However, when AML1b was coexpressed with 
AML1-ETO survivin activation was enhanced by five fold (lane 3). The 
activation was maintained when AML1-ETO was expressed alone (lane 4). 
The activation was repressed by the transfection of granulocytic 
differentiation transcription factor C/EBPα (lane 6-8). The expression of 
C/EBPα (lane 5) failed to induce any transcription of survivin promotor. This 
reduced effect could further be explained as forced expression of AML1 or 
C/EBPα overcomes the block in differentiation induced by AML1-ETO. This 
phenomenon explains that AML1-ETO acts as a putative transcriptional 
activator of survivin gene. In order confirm that effects shown here are 
specific, the expression of AMLl-ETO and C/EBPα for these conditions are 
shown (Fig.16, panel C & D) 
 52
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Figure 16.  AML1-ETO activates basal transcription of the survivin promotor. DNA 
sequence analysis of the 5’ flanking region of the survivin gene using the TFsearch 
algorithms (TRASER) revealed the presence of single putative AML1 binding site, 
TGTGGT. Numbering is from initiating ATG codon. The TGTGGT sequence is 
highlighted (A).  Luciferase assay was performed to show that AML1-ETO activates 
survivin promotor. 293T cells were cotransfected with pLuc-survivin reporter gene 
construct with pCMV-AML1B or pCDNA3-AML1-ETO expression vectors, pCDNA3-
C/EBPα (together with pCMV5 to normalize transfection efficiency). Promoter activity 
was measured as the ratio of the pLUC/rLUC (rLUC is the renilla luciferase internal 
plasmid activity). The promoter activity in the presence of the empty vector pCMV5 
plasmid was defined as 1 and the promoter activity in the presence of expression vectors 
for AML1/ETO, AML1B and C/EBPα was defined relative to that value. The results 
shown are the SEM of four different experiments (B). The western blot figure shows the 
expression of AML1-ETO in 293T cells which were co-transfected with various AML1-
ETO expression plasmids (details of these plasmids are given in the section material and 
methods). Kasumi-1 whole cell lysate was used as a positive control for AML1-ETO 
expression (C). Expression of C/EBPα in 293T cells for above experimental condition (D). 
 
3.5.2 AML1-ETO binds to the survivin promoter 
 
The above data confirmed that AML1-ETO induces survivin expression. We 
asked next whether AML1-ETO could bind to the AML1 core enhancer 
binding sequence, TGTGGT, on the survivin promotor. To address this 
possibility we performed an electromobility shift assay. We used the nuclear 
extracts from the Kasumi- 1 cells which has an endogenous AML1-ETO. The 
probes were labeled with non radioactive DIG flour (non- radioactive dye) and 
were incubated with the Kasumi-1 nuclear extract to identify the sequence 
specific binding. We also incubate the probe with NB4 promyelocyte cell line 
nuclear extract used as a negative control for AML1-ETO binding. The data 
strongly revealed that AML1-ETO binds to the core enhancer sequence of 
TGTGGT (Fig. 17 panel A, lane 2 & 3). The binding was competed away by a 
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125 fold excess of specific competitor (lane 4). The absence of a dimmer from 
NB4 nuclear extract (lane 5) further suggests the binding is specific for 
AML1-ETO. We further confirmed the data by using specific antibody, while 
as AML1-ETO binds to the core enhancer sequence of TGTGGT (Fig. 17 
panel B, lane 1), the bound complex was shifted by anti-AML1 antibody (lane 
2). The binding was competed away by a 125 fold excess of unlabelled 
specific competitor probe (lane 3). The data suggest while as AML1 binds to 
the core enhancer sequence, AML1-ETO retain the ability to bind to this 
sequence. This is the first report of its kind where we show that AML1-ETO 
binds to the core enhancer sequence of survivin promotor and activates it. 
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Figure 17. AML1-ETO binds to the survivin promotor. (A) Kasumi 1 nuclear extracts 
(lane 2, 3 & 4) and NB4 nuclear extract (lane 5) were subjected to EMSA using AML1 
core enhancer binding sequence as an oligonucleotide probe (lane 1-5). Oligos (15.5 fmol) 
were DIG labelled (non radioactive).  Probe was run alone (lane 1), or incubated with 10µg 
and 20µg of Kasumi-1 nuclear extract (lane 2 & 3) respectively. The reaction mixture was 
preincubated with a 150-fold molar excess of specific unlabeled oligonucleotide (lane 4), 
and nuclear extract from NB4 (lane 5). Position of free probe is indicated by arrow. (B) 
The physical binding of AML1-ETO fusion protein to survivin promoter was again 
analyzed by EMSA using specific antibody. The labelled oligonucleotide probe (lane 1-4) 
was incubated with 20 µg of kasumi1 nuclear extract (lane1); bound complex was 
incubated with anti-AML1 antibody respectively (lane 2). The specific binding was 
competed away by a 150-fold molar excess of unlabeled survivin oligonucleotide probe 
(lane 3). The position of the free probe and supershift are indicated by arrows. 
 
3.6 Knockdown of survivin expression overcomes AML1-ETO 
mediated inhibition of C/EBPα autoregulation 
 
The activation of survivin by AML1-ETO may act as a critical mediator of 
downregulation of granulocytic differentiation factor C/EBPα (Pabst et al., 
2001) and C/EBPα-dependent gene activation and autoregulation 
(Westendorf et al., 1998). The known functions of C/EBPα serve readout for 
our experiments. We analysed the effect of survivin knockdown on the 
transactivation potential of C/EBPα on its own promotor by performing a 
B)
1    2 3           
Unbound Probe
SS
Survivin probe                                  +       +    +
Kasumi1 NE                                      +       +    +
anti-AML1 +    + 
Specific comp +
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dual luciferase assay.  To test this, we used 293T cell line which lack 
endogenous C/EBPα (Erickson et al., 2001) and transiently transfected the 
cells with a minimal pTKα promoter construct containing two C/EBP sites 
cloned upstream of the luciferase reporter gene. Along with Luc- pTKα, we 
cotransfected C/EBPα expression plasmids either alone or with AML1-ETO 
vector plus shRNA against survivin or a control shRNA. Expression of the 
luciferase reporter gene was determined 24h post transfection. The results 
demonstrate that where as C/EBPα alone activates its own promoter (Fig. 
18A, lane 2); as expected the transactivation was inhibited by the expression 
of AML1-ETO (lane 3). However, when co-expressed with the shRNA 
against survivin the block in transactivation was significantly overcome (lane 
4). The control shRNA (lane 5) as well as vector alone and vector plus 
surviving shRNA had no significant effects (lane 6-7). To further confirm that 
these effects were specifically mediated by survivin knockdown, degradation 
of survivin by shRNA in 293T cells transfected with AML1-ETO is shown 
(fig. 18B, lane 1, 2 & 3). Unrelated control shRNA do not produce any 
degradation of survivin (lane 5). While as AML1-ETO significantly induces 
survivin expression (lane 4) in consistent with our finding. HL60 cell line 
lysate was used as a positive control for the experimentThe results 
demonstrate that AML1-ETO induced survivin expression that leads to the 
transcriptional inhibition of C/EBPα and its target genes which in turn is 
overcome by silencing survivin expression. The data points towards the 
critical role of survivin in mediating the AML1-ETO induced block of 
C/EBPα autoregulation.  
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Figure 18. Knockdown of survivin expression overcomes AML1−ETO mediated 
inhibition of C/EBPα autoregulation. A) Transient cotransfection of a p(C/EBP)2TK-
luciferase reporter construct with the cotransfection of pCDNA3-C/EBPα (lane 2-7). 
pCDNA3-C/EBPα alone (lane 2) plus pCDNA3-AML1-ETO (lane 3) and shRNA against 
survivin (0.5µg) (lane 4). A control shRNA (lane 5) and a pCDNA3 empty vector (lane 6) 
with survivin shRNA (lane 7). The pRL-0 renilla luciferase construct was cotransfected to 
normalize for transfection efficiency. Error bars indicate standard errors of the means. (B) 
Shows the depletion of survivin achieved in 293T cells after transfection of various 
amounts of shRNA against surviving and unrelated control shRNA. 
  
3.7 Repression of survivin expression by shRNA restores 
C/EBPα expression inhibited by AML1/ETO   
 
Next we investigated the effects of functional and stable knock-down of 
survivin by shRNA on the CEBPα expression. We cotransfected the AML1-
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ETO into U937 cells together with shRNA designed to target survivin. We 
observed the expression of survivin 48 hours after the transfection of survivin 
shRNA construct which revealed that survivin was effectively repressed (Fig. 
19 panel A, lane 4 & 5) as compared to the U937 transfected with control 
shRNA (6), HL60 cell line lysate was used as a positive control. The same blot 
was stripped off bound antibody and blotted with C/EBPα to check the 
expression. The data suggests as AML1-ETO effectively reduces C/EBPα 
expression (lane 3). The C/EBPα expression was dramatically enhanced by 
the survivin knockdown (lane 4 & 5). The control produces no substantial 
effect (lane 6). The expression of AML1-ETO and the transfection efficiency 
in U937 in this case are shown (Fig. 19 panels B & C). As we assume the 
restoration of C/EBPα drives U937 cells to terminal granulocytic 
differentiation. To confirm this aspect of the investigation we performed 
FACS staining for the surface expression of granulocytic marker, CD15, on 
U937 cells after 48 and 72 hours, the results are shown for 48h. Data revealed 
that CD15 expression enhances to a 10 fold when U937 cells were 
cotransfected with AML1-ETO and 0.5µg of survivin shRNA (fig 19D panel 
V), calculated after gating on CD15+ fraction from U937 cells (panel II). 
U937 transfected with AML1-ETO (panel IV) and AML1-ETO plus control 
shRNA (panel VI), empty vector (panel III) does not produce any significant 
increase. This enhancement of terminal differentiation leads to growth arrest as 
indicated by the cell count monitored for day 3 and day 5. The transfection of 
(0.5µg) of survivin shRNA leads to significant decrease in cell growth at day 5 
as compared to controls (fig 19E). Further, cytospin preparation for similar 
conditions showed signs of apoptosis at day 8 (fig 20A panel b), untransfected 
U937 cells (panel a) or AML1-ETO transfected cells (panel b), AML1-ETO 
plus control shRNA (panel d) does not show any nuclear fragmentation 
indicative of secondary necrosis. These results, thus, confirmed that AML1-
ETO induced survivin expression interferes with granulocytic program. 
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Removal of survivin restores biological function of C/EBPα protein 
inactivated by AML1-ETO, which is sufficient to induce terminal 
differentiation and growth arrest of myeloid leukaemia cells. Further, we asked 
how survivin depletion restores biological activity of C/EBPα. We designed 
synthetic oligos derived from Ubc9 promotor which possess a single CCAAT 
site (-500bp upstream of the initiating ATG). Ubc 9 is a well known SUMO 
conjugating enzyme which covalently links SUMO moiety to C/EBPα and 
activates it. We used U937 cells which express low levels of endogenous 
C/EBPα and transfected into these C/EBPα expression plasmid or 
cotransfected with AML1-ETO and survivin shRNA (0.5µg and 1µg), besides 
a control shRNA (fig. 20B). Whole cell extract was prepared 48h 
posttransfection and lysate was incubated with oligo probe and subjected to 
EMSA. No sequence specific binding was observed for condition where probe 
alone or U937 cell lysate transfected with AML1-ETO was incubated with 
probe (lane 1 & 2). However, when coexpressed with shRNA against survivin, 
sequence specific binding of C/EBPα increases on the probe dramatically 
(lane 3), binding enhances quantitatively with increased amount of transfected 
shRNA (lane 4). Sequence specific binding was effectively competed away by 
incubation of 125 fold excess of unlabelled probe (lane 5). Control shRNA do 
not show any significant increases comparable to that of survivin specific 
shRNA (lane 6). C/EBPα sequence specific binding was confirmed by the 
transfection of C/EBPαp42 expression plasmid which results in a sequence 
specific binding which was shifted by C/EBPα specific antibody (lane 7). This 
in vitro data indicate that survivin knockdown enhances C/EBPαp42 binding 
on the potential CCAAT binding sites including promoter of SUMO 
conjugating enzyme, Ubc9.  
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Figure 19. Inhibition of survivin expression by shRNA restores CEBPα protein 
expression. Western blot analysis performed 48 h after transfection on the whole cell 
lysates of U937 cells cotransfected with AML1-ETO and various amounts of shRNA 
designed to knock-down survivin and an unrelated control shRNA. (A) As shown the 
expression of survivin is inhibited by the shRNA while as unrelated control shRNA had no 
effect. The same blot was stripped and reprobed with anti C/EBPα (lower panel). To check 
the equal loading, same blot was again stripped off bound antibody and reprobed with anti-
calreticulin (lowest panel). (B) The expression of AML1-ETO in U937 from the lysate of 
fig. 5A, Kasumi 1 lysate was used as a positive control for AML1-ETO expression. (C) 
The transfection efficiency in U937 cells reached by AMAXA was 85% which was 
calculated by counting the cells first under normal light and then under fluorescent light 
using the same magnification and same field. (D) FACS analysis performed on U937 cells 
for CD15 expression after 48 hours. (E) Trypan blue staining showing the number of viable 
cells under different conditions 
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Figure 20. Morphology of U937 cells transfected with various plasmids. Day 8 
cytocentrifuge preparations of U937 cells stained with Wright–Giemsa.  U937 transfected 
with AML1-ETO (panel a) plus shRNA against survivin (panel b) showing immature as 
well as mature neutrophils or U937 alone at day 4 (panel c) plus control shRNA (panel d),  
empty vector (panel e) and empty vector plus survivin shRNA (panel f). Original 
magnification × 400. (B) EMSA for increased binding of C/EBPα on Ubc9 promotor. The 
labelled oligonucleotide probe 5'-AACTGGCCAATTGCAAGGGGTT-3' (lane 1-7) were 
incubated with 20 µg of U937 whole cell lysate prepared at 48h time point after 
transfection with various combination of plasmids (lane 2-6). Lysate were prepared by 
using 50mM Tris-Cl, pH 8.0, 1% NP40, 150mM NaCl, 100µg/ml leupeptin, 1mM PMSF, 
and 5mM orthovandate. Knockdown of survivin by shRNA, 0.5µg and 1 µg concentration 
is shown to result in enhanced binding to the probe. The bound complex of probe plus 
C/EBPα (introduced by transfection) was shifted by the incubation of 2 µg anti-C/EBPα 
U937+AML1/ETO+ Survivin shRNA 0.5ugb)U937+ AML1/ETOa)
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antibody (lane 7). The specific binding was competed away by a 150-fold molar excess of 
unlabeled Ubc9 oligonucleotide probe (lane 5). The position shift and supershift are 
indicated by arrows.  
 
3.8 Repression of survivin expression overcomes granulocytic 
differentiation block induced by AML1/ETO in human 
CD34+ cells 
 
Next we asked whether downregulation of survivin may have an effect on the 
AML1-ETO mediated inhibition of granulocytic differentiation in primary 
hematopoietic CD34+ cells. We used human CD34+ cells isolated from cord 
blood which shows 70%-80% positivity for CD34+ marker after MACS 
enrichment (Data not shown). These cells were grown in IMDM alone to 
block the background induction of survivin by cytokines and transfected with 
C/EBPα to induce granulocytic differentiation (Radomska et al., 1998) and 
cotransfected with PINCO-AML1-ETO expression plasmid alone or together 
with shRNA against survivin; besides the empty vector and control shRNA. 
The expression of survivin was detected as early as 24 post transfection of 
AML1-ETO (Fig. 21, A).The transfection efficiency reached by the AMAXA 
nucleofection in CD34+ was 50% (Fig. 21, B). Further we performed the 
FACS analysis on these cells 72 hours after the transfections. The data shows 
while as C/EBPα alone could induce significant increase of CD15 expression 
(Fig. 21 C, panel I), however, when co-transfected with AML1-ETO, CD15 
expression was significantly inhibited (panel II). This block in differentiation 
was overcome by the shRNA against survivin, 0.5µg and 1µg (panel III and 
IV). The control shRNA had no effect and AML1-ETO could effectively 
block the CD15 expression (panel V). The vector alone and the vector plus 
shRNA had no effect (panels VI and VII). We further validate this interesting 
finding by performing quantitative real time PCR for the expression of 
another granulocytic marker, myeloperoxidase (MPO). AML1 is known to 
activates transcription from enhancer core motifs (TGT/cGGY) which are 
present in a number of genes relevant to myeloid development including 
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myeloperoxidase (Frank et al., 1995). AML1-ETO, however, inhibits the 
activation of AML1 genes in a dominant negative manner. To investigate 
whether knockdown of survivin could overcome the dominant negative effect 
of AML1-ETO on the MPO expression. We again performed the transient 
transfections in CD34+ cells as described previously and isolated the RNA 
after 72 hours of transfection. Q-PCR data for MPO expression revealed that 
shRNA against survivin was able to overcome AML1-ETO mediated 
inhibition of the expression of MPO (Fig. 21 D, lane 4) while as it was able to 
inhibit the C/EBPα induced expression of MPO (lane 3). C/EBPα alone 
induces a significant increase in the expression of MPO (lane 2). The empty 
vectors and the control shRNA had no effect (lanes 5 and 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B)   CD34+ cells under normal light        CD34+ cells GFP transfected (50%) 
IB:survivin
50
IB:calreticulin
1         2          3 4
CD
34
+
CD
34
+ 
em
pt
y
ve
ct
or
CD
34
+A
M
L1
-E
TO
 (2
4h
)
C
D
34
+A
M
L1
-E
TO
 (4
8h
)
15
A)
 65
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Knockdown of survivin expression overcomes granulocytic differentiation 
block induced by AML1-ETO in human CD34+ cells. A) Western blot for the 
expression of survivin from the whole cell lysates of human CD34+ grown in IMDM 
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without cytokines and transfected with AML1/ETO (lane 3 & 4). The same blot was striped 
and reprobed with anti calreticulin to show equal loading (lower panel). B) Shows the 
transfection efficiency in CD34+ was calculated to be 50 %. C) Surface levels of CD15 on 
human CD34+ cells (thick line) 72h following cotransfections with C/EBPα (I-VII) and 
AML1-ETO (II); AML1-ETO plus shRNA against survivin (III- IV) or a control shRNA 
(V) or with an empty vector (VI) and empty vector plus survivin shRNA (VII). The thin 
lines show staining with isotype-matched control antibody on untransfected CD34+ cells. 
D) Q-PCR for the expression of MPO in CD34+ cells 72 h post transfection, the values on 
Y-axis are the fold increase. MPO expression is shown after the PCR samples were run on 
a 1% agarose gel, lower panel.  
 
3.9 Cytogenetic groups differ in their protein interaction 
networks  
 
All the proteins identified by mass spec screening from different AML 
cytogenetic groups were used to generate a wider protein interaction map by 
employing an ingenuity pathway finder software program, 
(www.ingenuity.com). Ingenuity database provides the protein-protein 
interaction maps on the basis of known literature which has been sited. These 
interactions of proteins are either confirmed by yeast hybrid screens or other 
methods. We used this software to investigate the protein-protein interactions 
among the proteins we identified from AML cytogenetic groups. This would 
give us an idea about the signaling pathways that may be involved in the 
process of leukemogenesis. Among the proteins matched to this database to 
generate Protein protein interaction maps (PPI) include, 19, 14, 18, 18, 40 
proteins identified from t(8;21), t(15;17), Inv(16), complex aberrant, 11q23 
and normal karyotype, respectively. The details of these proteins with their 
Ingenuity code names are ginven (Table 6). These proteins are represented by 
coloured shapes (nodes) in a network (Figure 22). Separate subnetworks for 
each cytogenetic group were generated; subnetworks from each AML 
subgroup were merged to obtain a wider network of interactions. The major 
regulating network and the signalling pathways contributed by these networks 
appeared to be MAPK8 and MYC for complex aberrant karyotype, JUN and 
MYC for Inv(16), TP53 for t(8;21), TP53, MYC, PRKAC (cAMP dependant 
kinase) for 11q23, (Figure 22, panel A, B, C and D). We identified different 
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hyperactive modules in the networks by singling out those proteins which, by 
a Proteomweaver analysis, expressed highest mean expression value in a 
network indicated by red colour intensity of a node (highlighted modules in 
Figure 22). In a complex aberrant karyotype, a module comprised of HDAC, 
E2F, TP53 and RBL2 is activated in the signature network of CK (Panel A). 
Similarly, in a signature network of Inv (16), serine (or cysteine) proteinase 
inhibitor (SERPINB1) is highly upregulated (mean spot intensity of 2.412 is 
highest in the network (refer to Figure 22, panel B). The module comprised of 
transcription factors C/EBP alpha (CEBPA), C-MYB and proteinase 3 
(PRTN3) may be a dysregulated module which is more likely the case as 
C/EBP alpha is mutated in 10% of all AML cases. Similarly for t(8;21) a 
module comprised of transcription elongation factor A (TCEA1) and FOS 
which belongs to the family of AP1 transcription factors appeared to be 
hyperactive. Interestingly the activated modules appear to be different in each 
cytogenetic group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Network representing Complex aberrant karyotype
 68
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Network representing Inv (16)
C. Network representing t(8;21)
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Figure 22. Biological networks generated for cytogenetic groups through Ingenuity 
database. Panels A, B, C, D, shows the molecular interaction networks generated for  
Complex aberrant karyotype, Inv(16), t(8;21), and 11q23 subtypes. The coloured nodes 
(shapes) are the proteins which we identify and that matched (Table 6) to the database of 
known proteins which are involved with the protein- protein interactions. The intensity of 
the node colour means the expression levels of a protein which we calculated from the gel 
spot analyser programme (ProteomWeaver as described in the material and methods) and 
used for the generation of these networks.  Rectangular boxes represent the signaling 
pathways influenced by these interactions. The highlighted lines represent the module ( a 
small interaction network) highly active in the network. Circular arrows or a line 
originating from one node and pointing back at that same node in a network arise from 
the ability of a gene product to act upon itself.  
 
 
 
This legend describes the Canonical pathway node shapes of the interaction networks. An 
arrow pointing from A to B in a network signifies that A causes B to activate. 
D. Network representing 11q23
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Table 6. The proteins identified from various cytogenetic groups which showed 
significant expression levels were used for generating protein interaction networks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t(8;21)                                                                                           Inv(16) 
1. Annexin A1 (ANXA1)                                                              1. Annexin A1 (ANXA1) 
2. Casein kinase 2                                                                          2. Calnexin (CANX) 
3. GAPHD                                                                                     3. Eukaryotic translational elongation factor 2 (EEF2) 
4. HNRPA2B1                                                                               4. Enolase (ENO1) 
5. HSPA5                                                                                       5. Apolipoprotein J ((CLU) 
6. HSPA8                                                                                       6. Ferritin light chain (FTL) 
7. Myeloid cell nuclear differentiation antigen (MNDA)              7. DNA helicase II (G22P1) 
8. Nucleophosmin (NPM1)                                                            8. HSPA5 
9. Prohibitin (PHB)                                                                        9. HSPCA 
10.Heat shock 60KDa protein 1 (HSPD1)                                    10. HSPCB 
11. Seine (or cysteine) proteinase inhibitor (SERPINB1)             11. Mafk (MAFK)  
12.Superoxide dismutase 2 (SOD2)                                              12. Serine (or cysteine) proteinase inhibitor (SERPINB1)        
13. Sorcin (SRI)                                                                             13. Upstream binding transcription factor, UBF1 (UBTF)       
14. Transgelin 2 (TAGLN2)                                                          14. Zinc finger protein 255 (ZNF 224)                                     
15. ATP synthase H+ transporting, mitochondrail (ATP 5D)       15. ATP synthase H+ transporting, mitochondrail (ATP 5D)  
16. HNRPF                                                                                    16. Protein disulphide isomerase (P4HB) 
17. Lamin B1 
18. FUSE binding protein 2( KHSRP) 
19. Electron transfer flavoprotein (ETFA) 
20. Transcription elongation factor A (TCEA1) 
21. HNRPG (RBMX) 
 
Complex aberrant                                                                           11q23 
 
1. ATP synthase H+ transporting, mitochondrail (ATP 5D           1. Actin beta (ACTB) 
2. Calnexin (CANX)                                                                       2. Rho-GDP dissociation inhibitor(GDI) beta (ARHGDIB) 
3. Glutathione-S  transferase Pi (GSTPI)                                       3. Calnexin (CANX) 
4. Hematopoietic cell- specific lyn substrate 1(HCLS1)                4. Actin depolymerising factor, destrin (DSTN) 
5. HNRPK                                                                                       5.Glutathione S-transferase pi (GSTP1) 
6. HSPA5                                                                                        6. HNRAPA2B1 
7. HSPA8                                                                                        7. HNRPH1 
8. HSPD1                                                                                        8. HSPA8 
9. Lamin B1 (LMNB1)                                                                   9. HSPCB 
10. Mitogen-activated protein kinase kinase 4 (MAP2K4)           10. Lactotransferrin (LTF) 
11. Prohibitin (PHB)                                                                      11.Phosphatidylethanolamine binding protein (PBP) 
12. Pyruvate kinase (PKM2)                                                          12.Phosphoglycerate mutase 1 (PGAM1) 
13. Peroxidoredoxin 6 (PRDX6)                                                   13.  Peroxidoredoxin 2 (PRDX2) 
14. Seine (or cysteine) proteinase inhibitor (SERPINB1)             14. Stress induced phosphoprotein1 (STIP1)                
15. Endoplasmin (TRA1)                                                               15. Zyxin (ZYX) 
16. Actin Beta (ACTB)                                                                  16. Lymphocyte cytosolic protein 1 (LCP1) 
17. Adenosine deaminase (ADA)                                                  17. Lymphocyte specific protein 1(LSP1) 
18. Annexin 1 (ANXA1) 
19. B-cell CLL/Lymphoma 11A (BCL11A) 
20. Diacylglycerol kinase, gamma(DGKG) 
21. HNRPD 
22. HNRPH1 
23. Moesin (MSN) 
24. Prohibitin (PHB) 
25. Peroxidoredoxin 3 (PRDX3) 
26. Ruv B-like 2 protein (RUVBL2) 
27. Zinc finger protein 224 (ZNF224) 
28. SUMO1/sentrin/ SMT3 specific protease 2(SENP2) 
29.  RAB8A 
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3.10 Cytogenetic groups showed significant differences in their 
protein expression patterns 
 
From the proteomic screen of various AML cytogenetic groups we identified 
a set of proteins as common targets which means they were identified among 
all groups of AML. These protein targets contribute to 65% of all identified 
proteome; however, they showed a significant quantitative variation in their 
expression pattern. For comparing the quantitative variations we used gel spot 
analyser software, ProteomeWeaver. This software measures protein 
expression levels of a spot by calculating its volume after reducing the 
background effect of staining. The spots representing common proteins were 
matched with the different gels from other AML cytogenetic groups and the 
standard deviation of matched spots were estimated. From this analysis we 
could identify significant differences between normal karyotype, CD34+ and 
healthy bone marrow. For example, growth arrest specific 6 protein identified 
from Normal karyotype shows a quantitative variation of 4 fold up in 
comparison to CK. Similarly c-myc promoter binding protein identified from 
NK and hematopoietic lineage specific protein identified from 11q23 patients 
shows a 2 fold enhanced expression in comparison to Inv (16) and CK 
respectively. hnRNPF identified from t(8;21) exhibits 1.5 fold increased 
expression in comparison to CK and t(15;17), (data not shown).  The 
expression of highly abundant proteins like alpha enolase, vimentin, GRP 78 
and protein disulphide isomerase shows highly significant quantitative 
variation between cytogenetic groups. P values calculated from the student’s 
t-test showed the mean deviation of alpha enolase and protein disulphide 
isomerase from other cytogenetic groups is significantly different. However, 
the data for GRP 78 and vimentin was determined as insignificant (Figure 23, 
panels A, B, C and D). This holds promise as these proteins can significantly 
distinguish t(8;21) and inv(16) from other subtypes. 
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Figure 23. Quantitative variation in the protein expression pattern for common targets  
between cytogenetic risk groups of AML. The calculated expression level(s) are the mean 
normalised spot volume(s) and standard deviation was calculated from a minimum of 3 
replicates of each protein. Each histogram represents coefficient of variation calculated as 
standard deviation/mean for alpha enolase (A), vimentin (B).  GRP 78 (C), protein 
disulphide isomerase (D) calreticulin (E). Calculated P value are obtained from the 
student’s t-test by comparing the means of two different AML subtypes, P<0.05 was 
considered significant. 
 
3.11 DIGE method identifies significant quantitative variation of 
expression pattern between t(15;17)- and inv(16)-AML 
 
We used a fluorescent based DIGE approach to detect the expression 
differences between t(15;17) and inv(16) patients. This method uses the 
fluorescent probes to label the protein. One of the advantages of this method is 
the accurate estimation of protein quantitation. Equal amount of protein 
extracts from t(15;17), inv(16) and a control comprising of protein mixture 
from both t(15;17) and Inv(16) (an internal pool standard) were labelled with 
Cy dyes and co-separated and visualised on one single 2D gel. Three 
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reciprocal gels were run in tandem. This analysis showed that some of the 
proteins exhibit visible quantitative variation in their expression (Figure 24). 
These spots were cut and later subjected to the mass spectrometry based 
identification. The details of these proteins with the mean spot volume(s) are 
given in the table below. Annexin II type I shows enhanced and significant 
quantitative variation from t(15;17), panel a.  Here again, vimentin shows the 
expression level higher in t(15;17) in comparison to inv(16) panel c, which 
further validate our method of quantisation of silver stained gels using 
proteomweaver, which showed almost similar results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. 2D-DIGE based expression pattern of proteins identified as common target of 
t(15;17)- and inv(16)-AML. Protein samples from t(15;17) and inv(16) were differentially 
labelled with Cy3 and Cy5. An internal pool standard was included which comprised equal 
amount of proteins from either sample and was labelled with Cy2. Panel a, b and c shows 
the differential expression of spots showing a visible expression differences. The Images 
are grey scale TIFF acquired from ProteomWeaver operated in a MFA mode. The table 
gives the details of the proteins with the mean spot volume identified from these spots. 
Internal pool standardInv(16) t(15;17)
c
Details and the mean expression volume(s) of the identified proteins from 2D-DIGE
No   Accession Protein Name            Theoretical Observed Theoretical Observed Mean Spot Volume
pI pI Mr[Da]         Mr[Da]        Inv(16)     t(15;17)
1. P27006      Annexin II type I             8.6               8.6             38414          38414          0.60         0.20
2. Q8N912      Hypothetical protein 11.21            8.44           18051            30500     0.30         2.10 
3. Q13951      Core Binding factor 2     6.23             6.23           21508            21508   0.14         0.81
4. Q525Q1     Stress 27KDa protein 7.32             7.32           20934            21012     0.24         0.88
5 P08670      Vimentin 5.06             5.06           53579  53579          1.20         0.75
6        O75123      KIAA0628                       8.46        7.04           61439            61439          1.05        0.60        
a
3
5
6
b
1
2
38414
8.6
30500
8.44
4
21508
6.23
21012
7.32
53579
5.06
61439
7.04
3
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3.12 Calreticulin, hnRPH1 and hnRNPA2/B1 showed a 
difference in their posttranslational modifications between 
cytogenetic risk groups 
 
Next we hypothesized whether the proteins identified as common targets of 
cytogenetic abnormalities show any differences between their MS data.  The 
mass spectrometer acquires ions (peptides) and generates a mass spectrum on 
the basis of mass to charge ratio of ions. We were interested to identify the 
differences in the raw mass spectrum of some of the common proteins 
identified. These differences can be mainly posttranslational modifications. In 
our proteomic screen we have identified calreticulin from t(8;21), t(15;17), 
inv(16), complex karyotype and normal karyotype. We analysed 5 different 
calreticulin MS spectra from 5 different patients with t(8;21), 4 MS spectra 
from Inv(16), 4 from t(15;17), 7 from normal karyotype and 4 from Complex 
aberrant karyotype. Figure 25a; shows the signature MS spectra of calreticulin 
labelled with the tryptic ions (the ions digested by trypsin). In order to identify 
the possible posttranslational modification differences of calreticulin between 
AML subtypes we searched calreticulin by MASCOT database and matched 
to our created database path in MSDB (a theoretical trypsin digestion database 
of calreticulin protein which includes an acetylation modification); a variable 
modification of acetylation was included. Among few potential peptides 
searched was a peptide (m/z) 2433AcetK, of the sequence 
186IDNSQVESGSLEDDWDFLPPK206. This comprises the peptide region 
between I186K206. The peptide has only one C-terminal lysine residue, K206 
that could serve as site for the acetylation. The Peptide Cutter theoretical 
digestion database (http//prospector.ucsf.edu) (Lominadze et al., 2005) 
revealed the presence of another ion (m/z) 2391 with the same sequence as 
that of 2433 ion. We suspect it to be the acetylated peptide which is shifted by 
42Da from a peptide (m/z) 2391. The reanalysis in a peak explorer for 
calreticulin MS spectra identified from t(8;21) discovered the acetylated peak 
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(m/z) 2433 to be present (Figure 25a, panel A and B). However, the similar 
procedure followed for MS spectra of calreticulin in other subtypes like 
t(15;17), complex karyotype, inv(16), and normal karyotype could not detect 
the acetylated peptide even though the peak (m/z) 2391 was present. This 
suggests that this modification is unique to t(8;21)-AML. This is a first report 
where we have shown that calreticulin posttranslational modification of 
acetylation could serve as a distinguished feature of t(8;21) AML.  
Next we selected hnRNPH1 which is already known to be modified by 
alternative processing of pre-mRNA splicing and by posttranslational 
modifications (Wang et al., 2004). We searched this protein within t(15;17), 
complex karyotype, 11q23, and t(8;21) AML cytogenetic groups for possible 
posttranslational modification. We analysed for hnRNP H1, 2 different MS 
spectra from t(15;17) patients, 3 spectra from 11q23, 2 spectra from complex 
aberrant, 3 spectra from normal karyotype. Unique to 11q23 patients a high 
intense peak, 2044, was consistently found which showed a difference of 
203Da from a genuine tryptic ion, 1841, (Figure 25b, panel A). This 
corresponds to the mass of O-linked acetyl hexosamine (O-GlcNAc) adduct, a 
modification covalently binding to hydroxyls of threonine or serine residues 
(Sagi et al., 2005). To further confirm whether the sequence of MH+1841 and 
2044 are matching, we sequenced their MS/MS spectra in data explorer 
(Figure 25b, B and C). The marked y and b ions confirm to the sequence 
150STGEAFVQFASQEIAEK166 between the region 150S151T166K for the 
1841 and 2044 ions. Further MS analysis of hnRNPH1 from other cytogenetic 
groups failed to show the presence of glycosylated (m/z) 2044 ion from the 
cytogenetic subgroups of t(15;17), t(5;6)del(9) and t(8;21) (Figure 25b, panel 
D, E and F). The peptide has typical RSTG motif binding sites for O-GlcNAc 
modification. To map the site for O-GlcNAc we sequenced the (m/z) 2044 by 
MS-MS. We suspect it to be either serine150 or threonine151 known sites for 
O-GlcNAc modifications. The N-terminal b1 ion which is serine 150, a signal 
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corresponding to (m/z) 392 (monoisotopic) will correspond to serine residual 
mass plus 203Da mass of O-GlcNAc, if present in MS/MS. However, we 
could not detect the corresponding signal instead the signal corresponding to 
b2 ion which must include the masses of ST+203Da mass (m/z) 448 
(monoisotopic) is present (Figure 25b, D). This confirms the site to be 
threonine 152. To further confirm the neutral losses of immonium and other 
ions, which should match for both the ions, we dissected the low (m/z) region 
and acquire the similar pattern (data not shown). Further, we confirm the O-
GlcNAc posttranslational modifications by Immunoblot analysis of whole cell 
lysates from 3 different 11q23 positive patients using O-GlcNAc specific 
antibody CTD110.6, which has been successfully used previously in 
immunoblots and ELISA. We detected a signal for O-GlcNAcylation at 48kD, 
(Figure 25b, panel G). In each of these experiments the specificity of 
CTD110.6 immunoreactivity was established by competitively blocking 
antibody binding with free GlcNAc. The same gel was reprobed for hnRNPH; 
we could confirm the detection of hnRNPH (48kD) in the same region where 
GlcNAcylation was detected (Figure 25b, panel H).   
           In a further analysis we investigated the methylation pattern of a 
protein hnRNPA2/B1 identified from various cytogenetic groups. We could 
identify hnRNPA2/B1 from NK, normal bone marrow, t(8;21) and Inv(16) 
patients. For hnRNPA2/B1 we analysed 2 MS spectra from t(8;21), 1 from 
11q23 patient, 1 from normal bone marrow, 4 from normal karyotype. The 
representative MS spectra of this protein with tryptic ions are shown (Figure 
25c). We investigated the spectra of hnRNPA2/B1 for methylation 
modification. We included methylation as a variable modification in a 
MASCOT search (data not shown); peptide cutter theoretical digestion 
database revealed ion (m/z) 1879 to be di-methylated. The detailed peak 
dissection of the real MS spectra of hnRNPA2/B1 discovered this peptide 
with a di-methylated signature with a sequence RGFGFVTFDDHDPVDK, a 
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peptide region between R153K168 (Figure25c, panel B, C and D). 
Methylation occurs predominantly on arginine and glycine rich RGG residues 
(Li et al., 1998a; Lin et al., 2000). This ion has N-terminal R153G154 motif 
which are the sites for di-methylation, RMeGMeFGFVTFDDHDPVDK. The ion 
must have shifted by a 28Da mass from (m/z) 1852. The detailed dissection 
across MS spectra of this protein revealed the presence of this ion, panel D. 
The theoretical digestion database revealed this ion has the same sequence as 
that of 1879 ion (data not shown). A similar analysis for hnRNPA2/B1 failed 
to detect the di-methylated ion from NK patients (data not shown). 
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A Zoom in view of the region selected showing the absence of 
acetylated ion 2433
D)
C) MS spectrum of calreticulin identified from t(15;17) AML showing absence of 2433 ion
A Zoom in view of the above marked region selected within MS spectra A: 
42Da shift of the acetylated ion 2391 of the sequence
IDNSQVESGSLEDDWDFLPPK
B)
A) MS spectrum of calreticulin identified in t(8;21) AML 
Ac
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Figure 25a.  Calreticulin acetylation in t(8;21) AML patients. Panel A shows the signature 
MS spectrum of calreticulin identified from t(8;21) AML. Each arrow represents the tryptic 
ion (peptide) matched to the theoretical database of trypsin digestion for calreticulin. Panel 
B shows the zoom in view of the MS spectrum of calreticulin identified from t(8;21) AML. 
(m/z) 2433 represents the acetylated ion. The m/z 2391 represents the ion of the same 
sequence shifted by a 42Da mass. Panel C, D, E, F and G for t(15;17), complex karyotype, 
inv(16), and normal karyotype AML show the calreticulin spectra where the acetylated 
2433 ion could not be detected even though the peak (m/z) 2391 is shown to be present. 
 
 
 
E) MS spectrum of calreticulin identified from complex karyotype AML
F) MS spectrum of calreticulin identified from inv(16) AML
Acetylated 2433 ion missing
G) MS spectrum of calreticulin identified from normal karyotype AML
G
Acetylated 2433 ion missing
Acetylated 2433 ion missing
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A zoomin view, showing the 2044 ion missing
E) MS spectrum of hnRNP H1 identified from an AML patient with a t(5;16),del (9)
2044 ion missing
F) MS spectrum of hnRNPH1 identified from an AMLpatient with t(8;12;21)
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Figure 25b. Modification of O-linked acetyl glucosamine of hnRNPH1 in 11q23 AML 
Patients. Panels A represent the MS spectra of hnRNPH1 identified from 11q23 showing 
the O-GlcNAcylation. The 203Da mass shift between (m/z) 1841 and 2044 corresponds to 
addition of O-GlcNAc. Panels B and C represents the MS-MS spectra of ions (m/z) 1841 
and (m/z) 2044 sequenced in data explorer. Panels D, E and F show the absence of 2044 ion 
corresponding to O-GlcNAc modification from t(15;17), t(5;16)del(9), t(8;12;21) . Panel G 
& H, validation of O-GlcNAcylation of hnRNPH1 detected by O-GlcNAc specific 
immunoblot from 11q23 patients. O-GlcNAc specific immunoblots were preformed using 
fresh protein RIPA lysates from 3 different 11q23 patients using anti-O-GlcNAc antibody 
CTD110.6. The specificity of the antibody for O-GlcNAc was tested by adding 10mM 
GlcNAc to the primary antibody dilution, Panel G. hnRNPH was detected from the same 
gel after reprobing with anti hnRNPH, Panel H. β- tubilin was used as a loading control. 
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Figure 25c. Di-methylattion of hnRNPA2/B1 in t(8;21) and inv(16) AML patients. Panels 
A, B, C and D represent the MS and Zoom in view of the MS spectra of hnRNPA2/B1 
identified from healthy bone marrow, t(8;21) and inv(16). The ion 1879 represents the di-
methylated ion which is shifted by 28Da from (m/z) 1852.     
            
A) MS of hnRNP A2/B1 identified from healthy bone marrow
C) MS of hnRNP A2/B1 identified from t(8;21) AML
(k)RMeGMeFGFVTFDDHDPVDK (I)
B)
A 28Da shift
D) MS spectra of hnRNP A2/B1 identified from inv(16) AML
Me2
Me2
Me2
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4 Discussion 
 
The systematic investigation of proteomic differences between various 
cytogenetic risk groups of AML has not been fully investigated. The 
mechanism how fusion proteins specifically alter the proteome of a normal 
cell is a subject of intense investigation. Characterisation of proteomic 
differences between set of AML patients with balanced chromosomal 
translocations is crucial given that any observed variation in its expression 
pattern may have prognostic and disease relevance (Nedelkov et al., 2005). 
Besides the identification of proteins/ and protein interaction pathways 
dysregulated by fusion proteins could provide disease relevant information 
regarding the signalling defects. Moreover, the biological characterisation of a 
potential therapeutic target could provide critical insight into the mechanism 
of the disease progression. The present study involves the mass spectrometry 
based characterisation of proteomic, bioinformatics and MS based analysis of 
posttranslational modifications of cytogenetic groups of AML. In this 
investigation we applied state of the art proteomic technology that includes 
the characterisation and identification of MS based peak pattern analysis to 
identify posttranslational protein modification differences between 
cytogenetic subgroups, differential gel electrophoresis (DIGE) to quantify the 
differential expression data and biological characterisation of AML1-ETO 
induced inhibitor of apoptosis protein (IAP) survivin given its immense 
therapeutic potential for AML.  
 We could identify significant differences in the proteome pattern which may 
discriminate cytogenetic risk groups with in themselves and from healthy bone 
marrow and CD34+ cells. The expression pattern of some of the proteins may 
correlate for diagnosis, prognosis and pathogenesis. The expression of 
hnRNPA2/B1, the RNA binding protein (Wang et al., 2006) and casein kinase 
1 alpha identified as a distinguished target of NK patients shows higher 
expression in NK patients in comparison to other subtypes where it is either 
 85
less expressed or absent may mean a positive discriminatory diagnostic marker 
for NK patients. Casein kinase 1 alpha have been reported to be involved in 
diverse cellular processes including cell cycle progression, apoptosis and 
cellular differentiation (Knippschild et al., 2005). However, for many of the 
other proteins which we report here as showing discriminatory pattern of 
expression among AML cytogenetic groups, their clinical significance remain 
to be investigated. For example, transcription factor MafK which we identified 
as a distinguished target of Inv(16) is known to promote the erythroid 
differentiation program of erythroleukemic cells and acts as a crucial regulator 
of many erythroid specific genes (Igarashi et al., 1995). B-cell CLL 
Lymphoma/Leukemia 11A, identified as a differential target of CK, functions 
as a myeloid and B-cell proto-oncogene. Its high expression in AML points 
towards a probable role in leukemogenesis and hematopoiesis (Satterwhite et 
al., 2001). During the proteomic screen of t(8;21) patients we identified the 
differential expression of apoptosis inhibitor protein (IAP) survivin from 
t(8;21). Because survivin has received great attention due to its potential 
therapeutic role in cancer we characterised this protein both mechanistically 
and biologically. We could show that by the knock down of survivin 
expression AML1-ETO mediated inhibition of granulocytic differentiation 
(Pabst et al., 2001) was overcome marked by the restoration of C/EBPα 
activity. C/EBPα in the absence of AML1-ETO autoregulates its own 
promotor (Legraverend et al., 1993; Smith et al., 1996) which is completely 
abolished by the presence of AML1-ETO (Timchenko et al., 1995). By the 
repression of survivin using short hairpin RNA we showed that AML1-ETO 
mediated inhibition of C/EBPα autoregulation of its own promotor was 
restored in a reporter assay. This restoration of C/EBPα activity and protein 
levels were sufficient to drive AML1-ETO positive leukemic blasts to 
neutrophilic differentiation and growth arrest. Thus explaining the lack of 
C/EBPα observed in AML1-ETO cells as critically mediated by the survivin 
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induction. AML1-ETO inhibits AML1-dependent activation of a granulocytic 
promoter like M-CSF (Westendorf et al., 1998). Interestingly, our results 
showed that AML1-ETO induces the expression of survivin in hematopoietic 
CD34+ cells and inhibition of survivin in these cells restores AML1 dependent 
transcription as confirmed by the Q-PCR data for the expression for MPO 
gene (Fig. 21, panel D). The induction of survivin by AML1-ETO may explain 
the phenomenon of extensive self renewal capacity observed in primary 
hematopoietic cells transformed with AML1-ETO. Besides the differential 
requirement of survivin for hematopoietic cell development in switching off 
the arm of definitive granulopoiesis (Gurbuxani et al., 2005; Tonks et al., 
2003). Further, we showed that AML1-ETO directly activates the basal 
transcription of the survivin gene in a transcriptional assay and that could 
explain the mechanism behind the overexpression of survivin in t(8;21) 
leukemia and in addition to higher expression in immature neutrophils 
(Altznauer et al., 2004). Not surprisingly, the higher expression of survivin in 
AML1-ETO transformed cells may explain that AML1-ETO like AML1 can 
act as a transcriptional activator (Frank et al., 1999; Klampfer et al., 1996; 
Yergeau et al., 1997) of survivin. AML1-ETO, otherwise, is perceived to be a 
well known transcriptional repressor of granulocytic genes (Meyers et al., 
1995). With the alteration of one allele of AML1 gene in t(8;21) leukemia 
resulting in AML1-ETO can efficiently inhibit AML1-dependent 
transcriptional activation as well as AML1 transcript variant AML1b (Frank et 
al., 1995; Meyers et al., 1995). However, AML1b effect on the survivin 
activation was negative providing a further poof of survivin is being involved 
principally in transformation program. This was further substantiated by a 
transcription assay that showed AML1-ETO in the absence of AML1b activate 
the transcription of survivin gene by 5 fold and the activation was repressed to 
2 fold in the presence of AML1b (Figure 16 panel B). The therapeutic 
potential of survivin as a targeted cancer therapy has been variedly exploited 
 87
in number of other cancers (Altieri, 2006). Molecular antagonists of survivin, 
including dominant-negative mutants and antisense have been reported to be 
associated with induction of apoptosis and inhibition of tumor growth in vivo, 
without going against normal cells (Altieri, 2003). Antisurvivin therapy is 
potentially a novel and attractive cancer treatment strategy for AML. Thus for, 
in various preclinical animal models trials, targeted anti survivin therapies 
have shown significant efficacy. However, the consequences of prolonged and 
stable survivin disruption (Altieri, 2006; Fukuda and Pelus, 2006) in t(8;21) 
leukemia which comprises of 40% AML have not been fully investigated.                        
             Molecular interaction maps are particularly useful for networks that 
include protein-protein binding and posttranslational modifications (e.g., 
phosphorylation). Both are important for nearly all of the proteins involved in 
DNA double-strand break signaling. Visualizing the regulatory circuits 
underlying cellular signaling may help identify key regulatory reactions and 
defects that can serve as targets for anticancer drugs (Pommier et al., 2005; 
Pommier et al., 2006). Mapping protein networks for various cytogenetic risk 
groups in vivo is critical for realizing the promise of subtype specific patient-
tailored molecular therapy. The proteins whose expression is significantly 
altered between cytogenetic groups could explore therapeutically relevant 
networks by providing an idea of dysregulation or hyperactivity in the 
network of intracellular signalling cascades (Petricoin et al., 2005). We 
applied this approach by employing one of the publicly available databases for 
generating the protein interactions. This approach is a robust assay for protein-
protein interaction (Parrish et al., 2006). Our results present cytogenetic 
specific signature networks and hyperactive modules. This provides valuable 
information regarding the dysregulation of signalling pathways based on 
differential proteome data. We used, from our proteomic data all the 
expressed proteins with the expression values, identified from cytogenetic 
groups to generate the protein interaction networks (Fig. 22). This data 
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provides the relevant information regarding the signalling networks that are 
influenced by the proteins showing abnormally higher expression. This 
information could also be exploited to investigate the signalling defects 
associated with the specific fusion proteins that could be important for the 
outcome of leukemia. Many proteins with oncogenic potential undergo a 
complex series of posttranslational modifications. Post-translational 
modifications are an important biological mechanism to produce various 
protein species with entirely different biological roles from a single gene 
(Schoneich, 2006). PTMs affect significantly a given protein in terms of its 
stability, function, half life, complex formation with other proteins the 
proteins, etc. Some of the common but important posttranslational 
modifications include phosphorylation, glycosylation, acetylation and 
methylation. Identification of these modifications presents a formidable 
challenge, but their determination could provide an indispensable insights into 
disease progression and possible key therapeutic and prognostic targets (Mann 
and Jensen, 2003). Proteomics combined with tandem LC/ MSMS and other 
online separation method makes it possible to dissect a given MS spectra of a 
protein and characterize the individual parts of post-translational 
modifications. Systemic analysis of post-translational modifications in various 
signaling pathways has been applied to illustrate the kinetics of modifications 
(Seo and Lee, 2004).  Information regarding the PTM differences which may 
correspond for prognosis, pathogenesis and therapeutic relevant targets has 
not been fully investigated in the context of cytogenetic risk groups of AML. 
We analysed the MS spectra of some of these commonly regulated proteins 
which we could identify among all the cytogenetic groups to look into 
possible differences in their MS spectra which may correspond for PTM 
differences (Fig. 25). Generally this information has been overlooked in 
majority of other high throughput proteomic screens reproted. For this 
analysis we selected calreticulin, hnRNPH1, and hnRNPA2/B1. Here we 
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show that calreticulin is modified by acetylation specifically in t(8;21)  AML. 
Increased calreticulin expression is correlated with the suppression of the 
granulocytic differentiation factor CEBPA in AML with inv(16) and t(8;21); 
calreticulin is also reported to interact with C/EBP alpha and C/EBP beta m-
RNA and represses them at protein level (Helbling et al., 2004; Helbling et al., 
2005). AML patients positive for t(8;21) have undetectable C/EBPalpha 
protein as compared to other subgroups of AML patients (Timchenko et al., 
2002; Timchenko et al., 1996). These effects may be in part due to the 
acetylation of calreticulin in t(8;21) which we reported here and not because 
of the nascent calreticulin protein alone. Posttranslational modification of 
glycosylation is an important regulatory modification of proteins. Altered 
glycosylation patterns are a hallmark of many types of cancers. Glycosylation 
modifications frequently affect expression, metabolism, functions, stability 
and/or cellular localization of glycoproteins in cancer cells contributing to 
their extensive proliferation. Therefore identification of glycosylation 
pathways has a potential for innovative  anti cancer therapies (Kukuruzinska 
and Lennon, 1998). hnRNPs are differentially regulated by alternative 
processing of pre-mRNA and by posttranslational modifications. However, 
among AML cytogenetic subgroups the significance at the posttranslational 
level is unknown except for hnRNP p43 which is known to get modified by 
O-GlcNAc (Vosseller et al., 2001; Wells et al., 2003). Here we could show 
that hnRNPH1 is reversibly modified by O-linked acetyl hexosamine 
(GlcNAc) in 11q23 positive patients. The covalent modification of 
intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) is a 
crucial regulatory posttranslational modification which play a role in apoptosis 
and modulate transcriptional and signal transduction events (Khidekel et al., 
2004), and may be associated with high therapeutic significance for AML in 
general and 11q23 translocations in particular. Methylation is a reversible and 
most stable posttranslational modification that occurs predominantly on 
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arginine and glycine rich RGG residues (Aoki et al., 2002; Li et al., 1998a; 
Lin et al., 2000). Methylation affects a variety of protein-protein interactions 
with distinct functional outcomes that make this modification potentially 
valuable in signaling networks not only for histone but also for non-histone 
proteins, such as p53 and TAF10 and hnRNPs (Chuikov et al., 2004; 
Kouskouti et al., 2004). Methylation pattern constitutes an important 
regulatory mechanism, large number of genes have been reported to be 
methylated in AML, and differences in the pattern of methylation has been 
reported between various subtypes of leukemia (Herman and Baylin, 2003; 
Wolffe and Matzke, 1999). The expression of hnRNPA2/B1 is a prognostic 
marker for early lung cancer detection (Zhou et al., 2001). Interestingly we 
report for the first time differences in the methylation pattern of hnRNPA2/B1 
in AML patients. Interestingly, the intensity of this peptide in t(8;21) and 
inv(16) is 10 and 20 fold higher than NBM. Even though the technique in 
itself is not quantitative unless the peptides are tagged, however, growing the 
blasts in culture and tagging invivo to accurately quantitate is the limitation to 
achieve this end.  Nonetheless the intensity value of methylated ion of 
hnRNPA2/B1 in t(8;21) and Inv(16) is in itself highly significant than NBM. 
                                  Our findings support the rational hypothesis that AML 
cytogenetic subgroups could be distinguished by proteome analysis. AML 
which is long believed to be heterogeneous in nature and we showed it 
differed at the basic biological setup and fusion proteins fundamentally alters 
the proteome. We further showed in our validation and characterisation 
experiments that survivin is a novel target of t(8;21) leukemia and AML1-
ETO directly regulates its expression to induce the differentiation block that 
could be overcome by silencing its expression.  Furthermore, the detection of 
modified peptides by MS peak import analysis could provide new insights 
into the functional modulation of these disease relevant proteins. 
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5 Summary 
Acute Myeloid Leukemia (AML) is characterized by specific cytogenetic 
aberrations that are strong determinants of prognostic outcome and therapeutic 
response. Because the pathological outcome of AML patients with cytogentic 
abnormalities differs considerably we hypothesized that their proteome may 
also differ specifically in their expression pattern, protein interaction pathways 
and posttranslational modifications. We performed this study using 42 AML 
patients diagnosed for various cytogenetic abnormalities based on two-
dimensional gel electrophoresis and MALDI TOF Tandem MS (MS/MS) 
analysis. We could identify significant differences in the proteome and 
posttranslational modifications of peptides, later confirmed by other methods, 
between cytogenetic groups. The interactome analysis based on computational 
bioinformatics reveals a major regulating networks, MAPK8 and MYC for 
complex aberrant karyotype, TP53 for t(8;21), TP53- MYC- PRKAC for 
11q23, JUN and MYC for Inv(16). We could show in our validation and 
characterisation experiments that survivin is a novel target of t(8;21) leukemia 
and AML1-ETO directly regulates its expression to induce the differentiation 
block that could be overcome by silencing its expression. Further, we 
analysed 42 MS spectra representative of hnRNPH1, Calreticulin and 
hnRNPA2/B1 in a peak explorer which reveals a cytogenetic specific 
posttranslational modification of β-O-linked N-acetyl glucosamine (O-
GlcNAc) of hnRNPH1 in AML patients with 11q23 translocation, an 
acetylation of calreticulin in t(8;21) translocation and methylation of 
hnRNPA2/B1 in patients with translocations of t(8;21) and inv(16). This 
report may lead to a new thinking about the AML pathogenesis as differences 
at PTM level could be used to distinguish different subtypes of AML besides 
for testing the therapeutic significance. Further, we characterised the 
biological role of survivin identified specifically from t(8;21) patients. We 
could show that AML1-ETO induces the expression of survivin both in a cell 
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line model and in primary human hematopoietic precursors. AML1-ETO 
activates the basal transcription of the survivin promoter and binds to the only 
AML1 core enhancer binding sequence, TGTGGT, in survivin promotor. 
Repression of AML1-ETO mediated induction of survivin expression by a 
specific short hairpin RNA restores C/EBPα protein and its basal 
transcriptional activity on its own promotor. This restoration differentiates 
AML1-ETO positive leukemic cells to terminal granulocytic differentiation 
and growth arrest. These observations indicate that the antiapoptotic survivin 
protein, which holds a great therapeutic promise, is a critical mediator of 
AML1-ETO induced defective granulopoiesis. Thus, proving that AML1-
ETO induces inhibition of granulocytic differentiation by activating survivin 
expression 
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6 Zusammenfassung 
 
Akut Myeloische Leukämien (AML) sind charakterisiert durch spezifische 
zytogenetische Veränderungen, die entscheidende Faktoren hinsichtlich der 
Prognose und dem Ansprechen auf Therapien darstellen. Es gibt beträchtliche 
Unterschiede im klinischen Bild von AML Patienten, die verschiedene 
zytogenetischen Abnormalitäten tragen. Aufgrund dieser bekannten 
Differenzen zwischen den einzelnen Subtypen, stellen wir die Hypothese auf, 
dass das Proteom dieser Patienten ebenfalls spezifische Unterschiede in 
seinem Expressionsmuster aufweist und des Weiteren, dass auch 
nachweisbare Unterschiede in den Interaktionen der einzelnen Proteine und 
deren posttranslationalen Modifikationen vorliegen. Unsere Studie umfasst 42 
AML Patienten, bei denen verschiedene zytogenetische Veränderungen, 
basierend auf  2D-Gelelektrophorese und MALDI TOF Tandem 
Massenspektrometrie (MS/MS) Analyse, nachgewiesen wurden. Mit Hilfe 
verschiedener Methoden konnten wir  zwischen den einzelnen 
zytogenetischen Gruppen in diesem Patientenkollektiv signifikante 
Unterschiede in deren Proteom und in den posttranslationalen Modifikationen 
verschiedener Proteine identifizieren. Bei der Analyse der Interaktionen der 
einzelnen Proteine, basierend auf bioinformatischen Berechnungen, konnten 
verschiedene bedeutende Netzwerke aufgedeckt werden, die jeweils spezifisch 
für die einzelnen zytogenetischen Gruppen sind. So involviert dieses 
Netzwerk beim komplex-aberranten Karyotyp die Proteine MAPK8 und 
MYC, in der Translokation t(8;21) das Protein TP53, in der Translokation 
11q23 die Proteine TP53, MYC and PRKAC und in der inv(16) die Proteine 
JUN und MYC. In unseren Charakterisierungs- und 
Bestätigungsexperimenten konnten wir zeigen, dass Survivin ein neues 
Zielprotein in Leukämien mit t(8;21) Translokationen ist.  Das Fusionsprotein 
AML1/ETO reguliert dabei direkt die Expression von Survivin und induziert 
dadurch einen Differenzierungsblock, welcher bei Ausschaltung der 
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AML1/ETO Expression überwunden werden kann. Des Weiteren ergab die 
Analyse von 42 Massenspektren repräsentativ für die Proteine hnRNPH, 
Calreticulin und hnRNPA2/B1 in einem Peak Explorer, dass bei AML 
Patienten mit 11q23 Translokation ß-O-gebundene N-acetyl-Glucosamine (O-
GlcNAc) des Proteins hnRNPH1 spezifische posttranslationale 
Modifikationen aufweisen und dass bei Patienten mit t(8;21) Translokationen 
Acetylierungen im Calreticulin nachweisbar sind. Außerdem weisen sowohl 
Patienten mit t(8;21) Translokationen als auch Patienten mit Inv(16) 
Methylierungen im Protein  hnRNPHA2/B1 auf. Diese Erkenntnisse können 
zu neuen Ansätzen hinsichtlich der Diagnostik und Therapie von AML 
Patienten führen, indem Unterschiede auf der Ebene translationaler 
Modifikationen von Proteinen zur Unterscheidung verschiedener AML 
Subtypen verwendet werden kann und daneben auch die therapeutische 
Signifikanz getestet werden kann. Darüber hinaus charakterisieren wir die 
biologische Rolle von Survivin und diese speziell bei Patienten mit t(8;21) 
Translokationen. Das Fusionsprotein AML1/ETO aktiviert die basale 
Transkription des Survivin Promotors und bindet dabei an die einzige 
spezifische AML1 Bindungs-Sequenz, TGTGGT, im Survivin Promotor. Die 
Unterdrückung der AML1/ETO mediierten Induktion der Survivin Expression 
mit Hilfe einer spezifischen  „short hairpin RNA“ führt zur Normalisierung 
des Transkriptionsfaktors C/EBPα auf Proteinebene und es zeigt sich auch die 
Rückkehr von C/EBPα zu seiner basalen Transkriptionsaktivität am eigenen 
Promotor. Diese Wiederherstellung der C/EBPα Funktionen führen zur 
Differenzierung leukämischer Zellen, die das Fusionsprotein AML1/ETO 
tragen, in neutrophile Granulozyten. Diese Beobachtungen deuten darauf hin, 
dass das antiapoptotische Protein Survivin, das große therapeutische 
Möglichkeiten verspricht, einen kritischen Faktor in der Vermittlung 
AML1/ETO induzierter Störung der Granulopoese darstellt. Dabei zeigt sich 
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das die AML1/ETO induziert Hemmung der granulozytären Differenzierung 
mit einer Aktivierung der Survivin Expression einhergeht. 
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9 Appendix 
 
1. Cell culture 
RPMI (PAA) 
10% Foetal bovine serum (Invitrogen) 
100µM Zinc sulphate (ZnSO4) (Sigma) 
1% Penicillin/Streptomycin (Gibco) 
2. Immunoblot 
RIPA laysis buffer (1% NP40, 0.5% Sodium deoxycholate, 0.1% SDS,   
0.15M NaCl, 5mM EDTA, 50mM Tris pH8.0 and dH2O) 
Phosphates inhibitor cocktail I and II (Sigma, USA) 
Proteinase inhibitor (Sigma) 
Bradford assay (BioRad Laboratories, Germany) 
2x loading dye 
1x running buffer and 1x Transfer buffer 
Nitrocellulose membrane (Millipore) 
1xTBST and 5% milk (Blocking buffer) 
2.5% milk in TBST (Washing buffer) 
ECL detection Kit (Amersham Biosciences, UK) 
Hyper film ECL (Amersham Biosciences, UK) 
3. 2D-gel electrophoresis 
Urea (Amersham bioscience, EU) 
Urea Lysis buffer (9.8M urea, 1% DTE, 4% CHAPS, 2.5mM EDTA and   
2.5mM EGTA) 
Resolyte (Amersham Biosciences) 
Bromophenol blue (Sigma, USA) 
IPG strips (pH 3-10 and pH 4-7) (Amersham Bioscience, Sweden) 
SDS PAGE (Gel running buffer 192mM Glycin, 25mM Tris and 0.5% SDS) 
DTE buffer and carbamylation buffer (1M Tris pH6.8, urea, 80% Glycerol) 
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20% SDS and ddH2O and add one half 0.2g DTE and to the other half 0.25 
iodoacetamide) 
4. Colloidal Coomassie blue stain (Sigma, USA) 
Fixing: 50% methanol and 10% acetic acid  
Staining: 0.1% Colloidal Coomassie, 2% H3PO4 , 10% Ammonium sulfate  
and 20% Methanol 
Destining: 25% Methanol 
5. Silver nitrate (Merck, Darmsadt, Germany) 
Silver stain 
50% Methanol, 12% Acetic acid and 37% Formaldehyde 
50% Ethanol 
200mg/L Sodium thiosulfate (Na2S2O3 5H2O) 
2g/L Silver nitrate (AgNO3) and 750µl/L 37% formaldehyde 
60g Sodium carbonate (Na2CO3), 5mg Na2S2O3 5H2O and 500µl  
formaldehyde 
50% Methanol and Acetic acid 
20% Ethanol and 12% Glycerine 
6. Peptides Extraction 
Acetonitrile (Aldirch) 
50% and 70% Acetonitrile 
50mM Ammonium bicarbonate (NH4HCO3)  
Trypsin enzyme reconstituted with ammonium bicarbonate (NH4HCO3) 
DHB Matrix  
20% Acetonitrile and 0.1% Trifluoroacetic acid (TFA) (Merck) 
20 mg/ml 2.5-dhydroxy-benzoicacid (DHB) (Merck) 
20 mg/ml 2-hydroxy-5-methoxy-benzoicacid (Merck) 
mix 9:1 DHB:HMB 
take 1µl of matrix with 1µl of peptide and spot 0,8µl on an anchor chip plate 
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CHCA Matrix 
50% Acetonitrile and 0.05% TFA (Solvent solution) 
8mg of CHCA (Sigma) in 200µl solvent solution 
2/3 of solvent solution mix 1/3 of CHCA solution 
Apply 0.5µl of matrix to the plate 
Add 0.5µl of the sample and dry 
7. Mass spectrometry 
PMF Reflex III MALD-TOF (Bruker Daltonics) 
MS/MS AB4700 and GPS explorer software (Applied Biosystems) 
Mascot database search (Matrix Science) 
8. Immunofluoresent 
Cytocentrifuge 
Glass slides  
P/R9 cells 
PBS (PAN) 
99% methanol and Acetone (Fixing) 
Permeabilized with 0.3% Triton X 
Block with 5% FBS in PBG (PBG=% BSA, 0.045% Fish-gelatine in 1X PBS) 
Primary antibody (Diluted in PBG and 2.5% FBS) anti-rabbit sc20796 Op18 
(Santa Cruz Biotechnology Inc.) 
Secondary antibody (Diluted in PBG and 2.5% FBS) (anti mouse α  
tubulin) Alexa Fluor (Molecular probes) 
488 Chicken anti-rabbit and Alexa Fluor 894 chicken anti-mouse  
IgG (Molecular probes) 
4´, 6´-Diamidino-2-phenylindole dihydrochloride( DAPI) (Molecular probes) 
9. FACS PI-cell cycle analysis 
Propidium Iodide (Sigma, USA) 
U937 and P/R9 cells   
Cell lysis buffer  
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0.1% Sodium citrate  
0.1% Triton X-100 
20µg/ml Propidium Iodide 
10. In-vitro kinase  
Protein A agarose beads (Roche) 
Kinase buffer (150mM NaCl, 1mM EDTA, 50mM tris-HCl, pH 7.5,  
10mMMgCl2 and 10mMDTT) 
Histone H1 (Upstate, Germany) 
Rb-fusion protein (Santa Cruz Biotechnology Inc.) 
ATP and [γ-32p] ATP 
11. siRNA  
Designed 2 Oligos (Gene accession number NM-203401) 
RNAiFect (Qiagen) 
Non silencing siRNA 
siRNA conjugated to rhodamine 
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